Lipids, pharmaceutical compositions containing them, and methods for delivering active pharmaceutical ingredients.

Lipids with specific structural features are used to create nanoparticles for efficient delivery of therapeutic agents like siRNA, mRNA, and miRNA, addressing the need for improved transfection methods.

JP7954317B2Active Publication Date: 2026-11-19NITTO DENKO CORP
View PDF 9 Cites 0 Cited by

Patent Information

Application Number
JP2025562005
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2023-04-28
Filing Date
2024-04-26
Publication Date
2026-11-19
Estimated Expiration
2044-04-26

AI Technical Summary

Technical Problem

There is a need for lipid molecules and compositions that can efficiently transfect nucleic acid molecules and other agents into cells and subjects.

Method used

The development of lipids with specific structural features, such as compounds of Formula I, which are used to prepare nanoparticles with enhanced transfection properties, including various alkyl and alkenyl groups, and pharmaceutically acceptable salts, for encapsulating active pharmaceutical ingredients like siRNA, mRNA, and miRNA.

Benefits of technology

The described lipids and nanoparticles effectively deliver active pharmaceutical ingredients to cells, enhancing transfection efficiency and efficacy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007954317000043
    Figure 0007954317000043
  • Figure 0007954317000044
    Figure 0007954317000044
  • Figure 0007954317000045
    Figure 0007954317000045
Patent Text Reader

Abstract

This application relates to lipids, pharmaceutical compositions containing them, and methods for delivering active pharmaceutical ingredients to cells or subjects.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] This application relates to lipids, pharmaceutical compositions containing lipids, and methods for delivering active pharmaceutical ingredients to cells or subjects. [Background technology]

[0002] Therapeutic agents, such as drug compounds, nucleic acid molecules, and other active pharmaceutical ingredients, act by being taken up by target cells, tissues, and organs. Transfection of drugs and molecules into cells is often a limiting step in therapeutic action.

[0003] For example, one way to perform nucleic acid transfection is to encapsulate it in lipid nanoparticles.

[0004] PCT Publication WO2017 / 049245 discloses a lipid having a head group linked to a nitrogen atom via a methylene group, a linear lipophilic tail linked to the nitrogen atom, and a branched lipophilic tail linked to the nitrogen atom, for example, compound R1 (hereinafter also referred to as "SM-102") of the following formula. PCT Publication WO2017 / 049245 discloses that compound R1 is useful for preparing nanoparticles having advantageous transfection properties.

[0005] [ka]

[0006] PCT Publication WO2016 / 210190 discloses a lipid having a head group linked to a nitrogen atom via a carbonyl group and two linear lipophilic tails linked to the nitrogen atom, for example, compound R2 of the following formula. PCT Publication WO2016 / 210190 discloses that compound R2 is useful for preparing nanoparticles with advantageous transfection properties.

[0007] [ka] SUMMARY OF THE INVENTION PROBLEMS TO BE SOLVED BY THE INVENTION

[0008] There is a continuing need for lipid molecules and compositions for efficient transfection of nucleic acid molecules and other agents into cells and subjects. MEANS FOR SOLVING THE PROBLEM

[0009] Summary The present disclosure relates to lipids that are useful for preparing nanoparticles with advantageous transfection properties.

[0010] Specifically, the present disclosure includes the following embodiments.

[0011] Embodiment 1. A compound of Formula I or a pharmaceutically acceptable salt thereof: [Chemical Formula] [In the formula, A 1 is [Chemical Formula] (the arrow indicates the connection to the carbonyl group, R 1 and R 2 are the same or different, and are hydrogen or hydroxy, R 3 , R 5 , R 6 , R 7 , R 8 , R 9 , and R 10 are the same or different, and are linear C1-C4 alkyl, R 4 is linear C1-C4 alkyl or -(CH2) p4 -OH, p1 and p2 are the same or different, and are each independently an integer selected from the group consisting of 1, 2, 3, and 4, p3 is an integer selected from the group consisting of 0, 1, 2, 3, and 4. p4 is an integer selected from the group consisting of 2, 3, and 4. X - (This is a pharmaceutically acceptable counter-anion.) Selected from the group consisting of, Each A 2 These are independently linear C4-C10 alkyl, linear C4-C10 alkenyl, or linear C4-C10 alkadienyl. m is an integer selected from the group consisting of 5, 6, 7, 8, and 9. n is an integer selected from the group consisting of 2, 3, 4, 5, and 6. A 3 is -OC(O)- or -C(O)O-, A 4 These are linear C10-C18 alkyl groups, linear C10-C18 alkenyl groups, or linear C10-C18 alkadienyl groups.

[0012] Embodiment 2. Each A 2 However, independently, the compound described in Embodiment 1, or a pharmaceutically acceptable salt thereof, is a linear C4-C10 alkyl group.

[0013] Embodiment 3. Each A 2 The compound described in Embodiment 1, or a pharmaceutically acceptable salt thereof, which is the same as the compound described in Embodiment 1.

[0014] Embodiment 4. A compound according to any of Embodiments 1 to 3, or a pharmaceutically acceptable salt thereof, wherein m is an integer selected from the group consisting of 5, 6, 7, and 8.

[0015] Embodiment 5. A compound according to any of Embodiments 1 to 4, or a pharmaceutically acceptable salt thereof, wherein n is an integer selected from the group consisting of 2, 3, 4, and 5.

[0016] Embodiment 6. A 4 -A 3 -(CH2) nA compound according to any one of Embodiments 1 to 5, or a pharmaceutically acceptable salt thereof, wherein the number of carbon atoms in - is 15 to 21.

[0017] Embodiment 7. A 1 but, [ka] (In the formula, arrows indicate connections to the carbonyl group.) A compound according to any one of Embodiments 1 to 6, or a pharmaceutically acceptable salt thereof, selected from the group consisting of the above.

[0018] Embodiment 8. A 1 but, [ka] (In the formula, arrows indicate connections to the carbonyl group.) A compound according to any one of Embodiments 1 to 6, or a pharmaceutically acceptable salt thereof, selected from the group consisting of the above.

[0019] Embodiment 9. A 1 but, [ka] (In the formula, arrows indicate connections to the carbonyl group.) A compound according to any one of Embodiments 1 to 6, or a pharmaceutically acceptable salt thereof, selected from the group consisting of the above.

[0020] Embodiment 10. A 1 but, [ka] (In the formula, arrows indicate connections to the carbonyl group.) A compound according to any one of Embodiments 1 to 6, or a pharmaceutically acceptable salt thereof, selected from the group consisting of the above.

[0021] Embodiment 11. The compound is selected from the group consisting of compound numbers 1 to 30 shown in Table 1 below, and is one of the compounds described in any one of Embodiments 1 to 10, or a pharmaceutically acceptable salt thereof: [Table 1] TIFF0007954317000010.tif208148TIFF0007954317000011.tif208147TIFF00079543170 00012.tif207147TIFF0007954317000013.tif208145TIFF0007954317000014.tif205146

[0022] Embodiment 12. The following: Lipid nanoparticles, and Pharmaceutical active ingredients encapsulated in lipid nanoparticles A pharmaceutical composition comprising the lipid nanoparticles comprising the compound described in any one of Embodiments 1 to 11, or a pharmaceutically acceptable salt thereof.

[0023] Embodiment 13. The pharmaceutical composition according to Embodiment 12, wherein the active pharmaceutical ingredient is selected from the group consisting of siRNA, mRNA, antisense oligonucleotides, and miRNA.

[0024] Embodiment 14. A method for delivering a pharmaceutical active ingredient to cells, comprising the step of bringing the pharmaceutical composition described in Embodiment 12 or 13 into contact with the cells.

[0025] Embodiment 15. A method for delivering a pharmaceutical active ingredient to a target requiring delivery of the pharmaceutical active ingredient, comprising the step of administering the pharmaceutical composition described in Embodiment 12 or 13 to the target. [Brief explanation of the drawing]

[0026] [Figure 1] Figure 1 shows the reaction scheme for the method of producing compound 1 as described in Example 1. [Figure 2]Figure 2 shows the reaction scheme for the method of producing compound 2 as described in Example 2. [Figure 3] Figure 3 shows the reaction scheme for the method of producing compound 3 as described in Example 3. [Figure 4] Figure 4 shows the reaction scheme for the method of producing compound 4 as described in Example 4. [Figure 5] Figure 5 shows the reaction scheme for the method of producing compound 5 as described in Example 5. [Figure 6] Figure 6 shows the reaction scheme for the method of producing compound 6 described in Example 6. [Figure 7] Figure 7 shows the reaction scheme for the method of producing compound 7 described in Example 7. [Figure 8] Figure 8 shows the reaction scheme for the method of producing compound 8 described in Example 8. [Figure 9] Figure 9 shows the reaction scheme for the method of producing compound 9 as described in Example 9. [Figure 10] Figure 10 shows the reaction scheme of the method for producing compound 10 as described in Example 10. [Figure 11] Figure 11 shows the reaction scheme of the method for producing compound 11 as described in Example 11. [Figure 12] Figure 12 shows the reaction scheme for the method of producing compound 12 as described in Example 12. [Figure 13] Figure 13 shows the reaction scheme of the method for producing compound 13 as described in Example 13. [Figure 14] Figure 14 shows the reaction scheme of the method for producing compound 14 as described in Example 14. [Figure 15] Figure 15 shows the reaction scheme of the method for producing compound 15 as described in Example 15. [Figure 16] Figure 16 shows the reaction scheme of the method for producing compound 16 as described in Example 16. [Figure 17] Figure 17 shows the reaction scheme of the method for producing compound 17 as described in Example 17. [Figure 18] Figure 18 shows the reaction scheme for the method of producing compound 18 described in Example 18. [Figure 19] Figure 19 shows the reaction scheme of the method for producing compound 19 as described in Example 19. [Figure 20] Figure 20 shows the reaction scheme for the method of producing compound 20 described in Example 20. [Figure 21] Figure 21 shows the reaction scheme for the method of producing compound 21 described in Example 21. [Figure 22] Figure 22 shows the reaction scheme for the method of producing compound 22 described in Example 22. [Figure 23] Figure 23 shows the reaction scheme for the method of producing compound 25 as described in Example 25. [Figure 24] Figure 24 shows the reaction scheme for the method of producing compound 28 described in Example 28. [Figure 25] Figure 25 shows the reaction scheme for the method of producing compound 30 described in Example 30. [Figure 26] Figure 26 shows a graph illustrating the distribution of Fluc mRNA after administration of LNP number 1. [Modes for carrying out the invention]

[0027] These and other embodiments are described in more detail below.

[0028] Detailed explanation compound Some embodiments of this disclosure relate to compounds of formula I or pharmaceutically acceptable salts thereof: [ka] [In the formula, A 1 teeth, [ka] (The arrow indicates connection to the carbonyl group.) R1 and R 2 They are the same or different, and are hydrogen or hydroxyl. R 3 , R 5 , R 6 , R 7 , R 8 , R 9 , and R 10 They are either the same or different, and are linear C1-C4 alkyl groups. R 4 This refers to linear C1-C4 alkyl or -(CH2) p4 -OH p1 and p2 are integers that are either the same or different, and are independently selected from the groups 1, 2, 3, and 4. p3 is an integer selected from the group consisting of 0, 1, 2, 3, and 4. p4 is an integer selected from the group consisting of 2, 3, and 4. X - (This is a pharmaceutically acceptable counter-anion.) Selected from the group consisting of, Each A 2 These are independently linear C4-C10 alkyl, linear C4-C10 alkenyl, or linear C4-C10 alkadienyl. m is an integer selected from the group consisting of 5, 6, 7, 8, and 9. n is an integer selected from the group consisting of 2, 3, 4, 5, and 6. A 3 is -OC(O)- or -C(O)O-, A 4 [These are linear C10-C18 alkyl groups, linear C10-C18 alkenyl groups, or linear C10-C18 alkadienyl groups.] Regarding.

[0029] In some embodiments, R 1 and R 2 This is a hydroxyl group.

[0030] In some embodiments, R 3 , R 5 , R 6, R 7 , R 8 , R 9 , and R 10 They are either the same or different, and are methyl or ethyl.

[0031] In some embodiments, R 4 This is methyl, ethyl, or -(CH2)2-OH.

[0032] In some embodiments, p1 and p2 are integers that are the same or different and independently selected from the group consisting of 1, 2, and 3. In some embodiments, p1 and p2 are the same or different and are 1 or 2. In some embodiments, p1 and p2 are 1.

[0033] In some embodiments, p3 is an integer independently selected from the group consisting of 0, 1, 2, and 3. In some embodiments, p3 is an integer independently selected from the group consisting of 0, 1, and 2. In some embodiments, p3 is 0 or 1.

[0034] In some embodiments, each A 2 These are independently linear C4-C9 alkyl, linear C4-C9 alkenyl, or linear C4-C9 alkadienyl. In some embodiments, each A 2 These are independently linear C8-C9 alkyl, linear C8-C9 alkenyl, or linear C8-C9 alkadienyl. In some embodiments, each A 2 These are independently linear C8-C10 alkyl, linear C8-C10 alkenyl, or linear C8-C10 alkadienyl. In some embodiments, each A 2 These are independently linear C4-C10 alkyl groups. In some embodiments, each A 2 These are independently linear C4-C9 alkyl groups. In some embodiments, each A 2 These are independently linear C7 or C8 alkyl groups. In some embodiments, each A in the compound 2 They are the same. For example, in some embodiments, each A 2 It is n-octyl.

[0035] In some embodiments, m is an integer selected from the group consisting of 5, 6, 7, and 8. In some embodiments, m is 5, 6, or 7. In some embodiments, m is 7 or 8. In some embodiments, m is 7.

[0036] In some embodiments, n is an integer selected from the group consisting of 2, 3, 4, and 5.

[0037] In some embodiments, A 4 A is a linear C11-C18 alkyl, a linear C11-C18 alkenyl, or a linear C11-C18 alkadienyl. In some embodiments, A 4 A is a linear C10-C17 alkyl, a linear C10-C17 alkenyl, or a linear C10-C17 alkadienyl. In some embodiments, A 4 These are linear C11-C17 alkyl groups, linear C11-C17 alkenyl groups, or linear C11-C17 alkadienyl groups.

[0038] In some embodiments, A 4 -A 3 -(CH2) n - The number of carbon atoms in is 15 to 21. In some embodiments, A 4 -A 3 -(CH2) n The number of carbon atoms in - is 16 to 20.

[0039] In some embodiments, A 1 teeth, [ka] (In the formula, arrows indicate connections to the carbonyl group.) It is selected from the group consisting of the following.

[0040] In some embodiments, A 1 teeth, [ka] (In the formula, arrows indicate connections to the carbonyl group.) It is selected from the group consisting of the following.

[0041] In some embodiments, A 1 teeth, [ka] (In the formula, arrows indicate connections to the carbonyl group.) It is selected from the group consisting of the following.

[0042] In some embodiments, A 1 teeth, [ka] (In the formula, arrows indicate connections to the carbonyl group.) It is selected from the group consisting of the following.

[0043] In some embodiments, A 1 teeth, [ka] (In the formula, arrows indicate connections to the carbonyl group.) It is selected from the group consisting of the following.

[0044] In some embodiments, A 1 teeth, [ka] (In the formula, arrows indicate connections to the carbonyl group.) It is selected from the group consisting of the following.

[0045] In some embodiments, X - This is a pharmaceutically acceptable counteranion selected from the group consisting of chloride ions, bromide ions, fluoride ions, iodide ions, nitrate ions, sulfate ions, methyl sulfate ions, phosphate ions, acetate ions, benzoate ions, citrate ions, glutamate ions, and lactate ions.

[0046] As used herein, the term “linear alkyl” refers to a linear hydrocarbyl radical of a saturated aliphatic group, which may be of any length unless otherwise specified. The term “linear C1-C4 alkyl” includes methyl, ethyl, n-propyl, and n-butyl. The term “linear C4-C10 alkyl” includes n-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, and n-decyl. As used herein, the term “linear C10-C18 alkyl” includes n-decyl, n-undecyl, n-dodecyl, n-tridecyl, n-tetradecyl, n-pentadecyl, n-hexadecyl, n-heptadecyl, and n-octadecyl.

[0047] As used herein, the term “linear alkenyl” refers to a linear hydrocarbyl radical having one carbon-carbon double bond, which may be of any length unless otherwise specified. The term “linear C4-C10 alkenyl” refers to 1-butenyl, 2-butenyl, 3-butenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 1-heptenyl, 2-heptenyl, 3-heptenyl, 4-heptenyl, 5-heptenyl, 6-heptenyl, 1-octenyl, 2 Includes -octenyl, 3-octenyl, 4-octenyl, 5-octenyl, 6-octenyl, 7-octenyl, 1-nonenyl, 2-nonenyl, 3-nonenyl, 4-nonenyl, 5-nonenyl, 6-nonenyl, 7-nonenyl, 8-nonenyl, 1-decenyl, 2-decenyl, 3-decenyl, 4-decenyl, 5-decenyl, 6-decenyl, 7-decenyl, 8-decenyl, and 9-decenyl. The term "linear C10-C18 alkenyl" refers to 1-decenyl, 2-decenyl, 3-decenyl, 4-decenyl, 5-decenyl, 6-decenyl, 7-decenyl, 8-decenyl, 9-decenyl, 1-undecenyl, 2-undecenyl, 3-undecenyl, 4-undecenyl, 5-undecenyl, 6-undecenyl, 7-undecenyl, 8-undecenyl, 9-undecenyl, 10-undecenyl, 1-dodecenyl, 2-dodecenyl, 3-dodecenyl, 4-dodecenyl, 5-dodecenyl, 6-dodecenyl, 7-dodecenyl, 8-dodecenyl, 9-dodecenyl, 10-dodecenyl, 11-dodecenyl, 1-tridecenyl, 1-tridecenyl, 2-tridecenyl Lu, 3-tridecenyl, 4-tridecenyl, 5-tridecenyl, 6-tridecenyl, 7-tridecenyl, 8-tridecenyl, 9-tridecenyl, 10-tridecenyl, 11-tridecenyl, 12-tridecenyl, 1-tetradecenyl, 2-tetradecenyl, 3-tetradecenyl, 4-tetradecenyl, 5-tetradecenyl, 6-tetradecenyl, 7-tetradecenyl, 8-tetradecenyl, 9-tetradecenyl, 10-tetradecenyl, 11-tetradecenyl, 12-tetradecenyl, 13-tetradecenyl, 1-pentadecenyl, 2-pentadecenyl, 3-pentadecenyl, 4-pentadecenyl, 5-pentadecenyl, 6-pentadecenyl,7-pentadecenyl, 8-pentadecenyl, 9-pentadecenyl, 10-pentadecenyl, 11-pentadecenyl, 12-pentadecenyl, 13-pentadecenyl, 14-pentadecenyl, 1-hexadecenyl, 2-hexadecenyl, 3-hexadecenyl, 4-hexadecenyl, 5-hexadecenyl, 6-hexadecenyl, 7-hexadecenyl Hexadecenyl, 8-Hexadecenyl, 9-Hexadecenyl, 10-Hexadecenyl, 11-Hexadecenyl, 12-Hexadecenyl, 13-Hexadecenyl, 14-Hexadecenyl, and 15-Hexadecenyl, 1-Heptadecenyl, 2-Heptadecenyl, 3-Heptadecenyl, 4-Heptadecenyl, 5-Heptadecenyl, 6-Heptadecenyl Butadecenyl, 7-heptadecenyl, 8-heptadecenyl, 9-heptadecenyl, 10-heptadecenyl, 11-heptadecenyl, 12-heptadecenyl, 13-heptadecenyl, 14-heptadecenyl, 15-heptadecenyl, 16-heptadecenyl, 1-octadecenyl, 2-octadecenyl, 3-octadecenyl, 4-octadecenyl This includes tadecenyl, 5-octadecenyl, 6-octadecenyl, 7-octadecenyl, 8-octadecenyl, 9-octadecenyl, 10-octadecenyl, 11-octadecenyl, 12-octadecenyl, 13-octadecenyl, 14-octadecenyl, 15-octadecenyl, 16-octadecenyl, and 17-octadecenyl.

[0048] As used herein, the term “linear alkadinyl” refers to a linear hydrocarbyl radical having two carbon-carbon double bonds, which may be of any length unless otherwise specified. The term "linear C4-C10 alkadienyl" refers to 1,3-butadienyl, 1,3-pentadienyl, 1,4-pentadienyl, 2,4-pentadienyl, 1,3-hexadienyl, 1,4-hexadienyl, 1,5-hexadienyl, 2,4-hexadienyl, 2,5-hexadienyl, 3,5-hexadienyl, 1,3-heptadienyl, 1,4-heptadienyl, 1,5-heptadienyl, 1,6-heptadienyl, 2,4-heptadienyl, 2,5-heptadienyl, 2,6-heptadienyl, 3,5- Heptadienyl, 3,6-heptadienyl, 4,6-heptadienyl, 1,3-octadienyl, 1,4-octadienyl, 1,5-octadienyl, 1,6-octadienyl, 1,7-octadienyl, 2,4-octadienyl, 2,5-octadienyl, 2,6-octadienyl, 2,7-octadienyl, 3,5-octadienyl, 3,6-octadienyl, 3,7-octadienyl, 4,6-octadienyl, 4,7-octadienyl, 5,7-octadienyl, 1,3-nonadienyl, 1,4-nonadienyl Dienyl, 1,5-nonadienyl, 1,6-nonadienyl, 1,7-nonadienyl, 1,8-nonadienyl, 2,4-nonadienyl, 2,5-nonadienyl, 2,6-nonadienyl, 2,7-nonadienyl, 2,8-nonadienyl, 3,5-nonadienyl, 3,6-nonadienyl, 3,7-nonadienyl, 3,8-nonadienyl, 4,6-nonadienyl, 4,7-nonadienyl, 4,8-nonadienyl, 5,7-nonadienyl, 5,8-nonadienyl, 6,8-nonadienyl, 1,3-decadienyl, 1,4- Decadienyl, 1,5-decadienyl, 1,6-decadienyl, 1,7-decadienyl, 1,8-decadienyl, 1,9-decadienyl, 2,4-decadienyl, 2,5-decadienyl, 2,6-decadienyl, 2,7-decadienyl, 2,8-decadienyl, 2,9-decadienyl, 3,5-decadienyl, 3,6-decadienyl, 3,7-decadienyl, 3,8-decadienyl, 3,9-decadienyl, 4,6-decadienyl, 4,7-decadienyl, 4,8-decadienyl, 4,9-decadienyl, 5,The term "linear C10-C18 alkadienyl" includes 7-decadienyl, 5,8-decadienyl, 5,9-decadienyl, 6,8-decadienyl, 6,9-decadienyl, and 7,9-decadienyl. ,7-decadienyl, 4,8-decadienyl, 4,9-decadienyl, 5,7-decadienyl, 5,8-decadienyl, 5,9-decadienyl, 6,8-decadienyl, 6,9-decadienyl, 7,9-decadienyl, 1,3-undecadienyl, 1,4-undecadienyl, 1,5-undecadienyl, 1,6-undecadienyl, 1,7-undecadienyl, 1,8-undecadienyl, 1,9-undecadienyl, 1,10-undecadienyl, 2,4-undecadienyl, 2,5-undecadienyl, 2,6- Undecadienyl, 2,7-Undecadienyl, 2,8-Undecadienyl, 2,9-Undecadienyl, 2,10-Undecadienyl, 3,5-Undecadienyl, 3,6-Undecadienyl, 3,7-Undecadienyl, 3,8-Undecadienyl, 3,9-Undecadienyl, 3,10-Undecadienyl, 4,6-Undecadienyl, 4,7-Undecadienyl, 4,8-Undecadienyl, 4,9-Undecadienyl, 4,10-Undecadienyl, 5,7-Undecadienyl, 5,8-Undecadienyl , 5,9-undecadienyl, 5,10-undecadienyl, 6,8-undecadienyl, 6,9-undecadienyl, 6,10-undecadienyl, 7,9-undecadienyl, 7,10-undecadienyl, 8,10-undecadienyl, 1,3-dodecadienyl, 1,4-dodecadienyl, 1,5-dodecadienyl, 1,6-dodecadienyl, 1,7-dodecadienyl, 1,8-dodecadienyl, 1,9-dodecadienyl, 1,10-dodecadienyl, 1,11-dodecadienyl, 2,4-dodecadienyl, 2,5-Dodecadienyl, 2,6-Dodecadienyl, 2,7-Dodecadienyl, 2,8-Dodecadienyl, 2,9-Dodecadienyl, 2,10-Dodecadienyl, 2,11-Dodecadienyl, 3,5-Dodecadienyl, 3,6-Dodecadienyl, 3,7-Dodecadienyl, 3,8-Dodecadienyl, 3,9-Dodecadienyl, 3,10-Dodecadienyl, 3,11-Dodecadienyl, 4,6-Dodecadienyl, 4,7-Dodecadienyl, 4,8-Dodecadienyl, 4,9-Dodecadienyl, 4,10-Dodecadienyl, 4,11-Dodecadienyl, 5,7-D Decadienyl, 5,8-dodecadienyl, 5,9-dodecadienyl, 5,10-dodecadienyl, 5,11-dodecadienyl, 6,8-dodecadienyl, 6,9-dodecadienyl, 6,10-dodecadienyl, 6,11-dodecadienyl, 7,9-dodecadienyl, 7,10-dodecadienyl, 7,11-dodecadienyl, 8,10-dodecadienyl, 8,11-dodecadienyl, 9,11-dodecadienyl, 1,3-tridecadienyl, 1,4-tridecadienyl, 1,5-tridecadienyl, 1,6-tridecadienyl, 1,7-tridecadienyl, 1,8-tridecadienyl, 1,9-tridecadienyl, 1,10-tridecadienyl, 1,11-tridecadienyl, 1,12-tridecadienyl, 2,4-tridecadienyl, 2,5-tridecadienyl, 2,6-tridecadienyl, 2,7-tridecadienyl, 2,8-tridecadienyl, 2,9-tridecadienyl, 2,10-tridecadienyl, 2,11-tridecadienyl, 2,12-tridecadienyl, 3,5-tridecadienyl, 3,6-tridecadienyl, 3,7-tridecadienyl, 3,8-tridecadienyl, 3,9-tridecadienyl Enyl, 3,10-tridecadienyl, 3,11-tridecadienyl, 3,12-tridecadienyl, 4,6-tridecadienyl, 4,7-tridecadienyl, 4,8-tridecadienyl, 4,9-tridecadienyl, 4,10-tridecadienyl, 4,11-tridecadienyl, 4,12-tridecadienyl, 5,7-tridecadienyl, 5,8-tridecadienyl, 5,9-tridecadienyl, 5,10-tridecadienyl, 5,11-tridecadienyl, 5,12-tridecadienyl, 6,8-tridecadienyl, 6,9-tridecadienyl, 6,10-Tridecadienyl, 6,11-Tridecadienyl, 6,12-Tridecadienyl, 7,9-Tridecadienyl, 7,10-Tridecadienyl, 7,11-Tridecadienyl, 7,12-Tridecadienyl, 8,10-Tridecadienyl, 8,11-Tridecadienyl, 8,12-Tridecadienyl, 9,11-Tridecadienyl, 9,12-Tridecadienyl, 10,12-Tridecadienyl, 1,3-Terradecadienyl, 1,4-Terradecadienyl, 1,5-Terradecadienyl, 1,6-Terradecadienyl, 1,7-Terradecadienyl Lu, 1,8-tetradecadienyl, 1,9-tetradecadienyl, 1,10-tetradecadienyl, 1,11-tetradecadienyl, 1,12-tetradecadienyl, 1,13-tetradecadienyl, 2,4-tetradecadienyl, 2,5-tetradecadienyl, 2,6-tetradecadienyl, 2,7-tetradecadienyl, 2,8-tetradecadienyl, 2,9-tetradecadienyl, 2,10-tetradecadienyl, 2,11-tetradecadienyl, 2,12-tetradecadienyl, 2,13-tetradecadienyl, 3,5-tetradecadienyl, 3 ,6-tetradecadienyl, 3,7-tetradecadienyl, 3,8-tetradecadienyl, 3,9-tetradecadienyl, 3,10-tetradecadienyl, 3,11-tetradecadienyl, 3,12-tetradecadienyl, 3,13-tetradecadienyl, 4,6-tetradecadienyl, 4,7-tetradecadienyl, 4,8-tetradecadienyl, 4,9-tetradecadienyl, 4,10-tetradecadienyl, 4,11-tetradecadienyl, 4,12-tetradecadienyl, 4,13-tetradecadienyl, 5,7-tetradecadienyl, 5,8 -Tetradecadienyl, 5,9-Tetradecadienyl, 5,10-Tetradecadienyl, 5,11-Tetradecadienyl, 5,12-Tetradecadienyl, 5,13-Tetradecadienyl, 6,8-Tetradecadienyl, 6,9-Tetradecadienyl, 6,10-Tetradecadienyl, 6,11-Tetradecadienyl, 6,12-Tetradecadienyl, 6,13-Tetradecadienyl, 7,9-Tetradecadienyl, 7,10-Tetradecadienyl, 7,11-Tetradecadienyl, 7,12-Tetradecadienyl, 7,13-Tetradecadienyl, 8,10-Tetadecadienyl, 8,11-Tetadecadienyl, 8,12-Tetadecadienyl, 8,13-Tetadecadienyl, 9,11-Tetadecadienyl, 9,12-Tetadecadienyl, 9,13-Tetadecadienyl, 10,12-Tetadecadienyl, 10,13-Tetadecadienyl, 11,13-Tetadecadienyl, 1,3-Pentadecadienyl, 1,4-Pentadecadienyl, 1,5-Pentadecadienyl, 1,6-Pentadecadienyl, 1,7-Pentadecadienyl, 1,8-Pentadecadienyl, 1,9-Pentadecadienyl , 1,10-pentadecadienyl, 1,11-pentadecadienyl, 1,12-pentadecadienyl, 1,13-pentadecadienyl, 1,14-pentadecadienyl, 2,4-pentadecadienyl, 2,5-pentadecadienyl, 2,6-pentadecadienyl, 2,7-pentadecadienyl, 2,8-pentadecadienyl, 2,9-pentadecadienyl, 2,10-pentadecadienyl, 2,11-pentadecadienyl, 2,12-pentadecadienyl, 2,13-pentadecadienyl, 2,14-pentadecadienyl, 3,5-pentadecadienyl, 3,6-pentadecadienyl, 3,7-pentadecadienyl, 3,8-pentadecadienyl, 3,9-pentadecadienyl, 3,10-pentadecadienyl, 3,11-pentadecadienyl, 3,12-pentadecadienyl, 3,13-pentadecadienyl, 3,14-pentadecadienyl, 4,6-pentadecadienyl, 4,7-pentadecadienyl, 4,8-pentadecadienyl, 4,9-pentadecadienyl, 4,10-pentadecadienyl, 4,11-pentadecadienyl, 4,12-pentadecadienyl, 4,13-pentadecadienyl, 4, 14-Pentadecadienyl, 5,7-Pentadecadienyl, 5,8-Pentadecadienyl, 5,9-Pentadecadienyl, 5,10-Pentadecadienyl, 5,11-Pentadecadienyl, 5,12-Pentadecadienyl, 5,13-Pentadecadienyl, 5,14-Pentadecadienyl, 6,8-Pentadecadienyl, 6,9-Pentadecadienyl, 6,10-Pentadecadienyl, 6,11-Pentadecadienyl, 6,12-Pentadecadienyl, 6,13-Pentadecadienyl, 6,14-Pentadecadienyl, 7,9-Pentadecadienyl, 7,10-Pentadecadienyl, 7,11-Pentadecadienyl, 7,12-Pentadecadienyl, 7,13-Pentadecadienyl, 7,14-Pentadecadienyl, 8,10-Pentadecadienyl, 8,11-Pentadecadienyl, 8,12-Pentadecadienyl, 8,13-Pentadecadienyl, 8,14-Pentadecadienyl, 9,11-Pentadecadienyl, 9,12-Pentadecadienyl, 9,13-Pentadecadienyl, 9,14-Pentadecadienyl, 10,12-Pentadecadienyl, 10,13-Pentadecadienyl, 10,14-Pentadecadienyl 1,13-pentadecadienyl, 11,14-pentadecadienyl, 12,14-pentadecadienyl, 1,3-hexadecadienyl, 1,4-hexadecadienyl, 1,5-hexadecadienyl, 1,6-hexadecadienyl, 1,7-hexadecadienyl, 1,8-hexadecadienyl, 1,9-hexadecadienyl, 1,10-hexadecadienyl, 1,11-hexadecadienyl, 1,12-hexadecadienyl, 1,13-hexadecadienyl, 1,14-hexadecadienyl, 1,15-hexadecadienyl, 2, 4-Hexadecadienyl, 2,5-Hexadecadienyl, 2,6-Hexadecadienyl, 2,7-Hexadecadienyl, 2,8-Hexadecadienyl, 2,9-Hexadecadienyl, 2,10-Hexadecadienyl, 2,11-Hexadecadienyl, 2,12-Hexadecadienyl, 2,13-Hexadecadienyl, 2,14-Hexadecadienyl, 2,15-Hexadecadienyl, 3,5-Hexadecadienyl, 3,6-Hexadecadienyl, 3,7-Hexadecadienyl, 3,8-Hexadecadienyl, 3,9-Hexadecadienyl, 3,10- Hexadecadienyl, 3,11-Hexadecadienyl, 3,12-Hexadecadienyl, 3,13-Hexadecadienyl, 3,14-Hexadecadienyl, 3,15-Hexadecadienyl, 4,6-Hexadecadienyl, 4,7-Hexadecadienyl, 4,8-Hexadecadienyl, 4,9-Hexadecadienyl, 4,10-Hexadecadienyl, 4,11-Hexadecadienyl, 4,12-Hexadecadienyl, 4,13-Hexadecadienyl, 4,14-Hexadecadienyl, 4,15-Hexadecadienyl, 5,7-Hexadecadienyl, 5,8-Hexadecadienyl, 5,9-Hexadecadienyl, 5,10-Hexadecadienyl, 5,11-Hexadecadienyl, 5,12-Hexadecadienyl, 5,13-Hexadecadienyl, 5,14-Hexadecadienyl, 5,15-Hexadecadienyl, 6,8-Hexadecadienyl, 6,9-Hexadecadienyl, 6,10-Hexadecadienyl, 6,11-Hexadecadienyl, 6,12-Hexadecadienyl, 6,13-Hexadecadienyl, 6,14-Hexadecadienyl, 6,15-Hexadecadienyl, 7,9-Hexadecadienyl, 7,10-Hexadecadienyl, 7,11-Hexadecadienyl, 7,12-Hexadecadienyl, 7,13-Hexadecadienyl, 7,14-Hexadecadienyl, 7,15-Hexadecadienyl, 8,10-Hexadecadienyl, 8,11-Hexadecadienyl Nyl, 8,12-hexadecadienyl, 8,13-hexadecadienyl, 8,14-hexadecadienyl, 8,15-hexadecadienyl, 9,11-hexadecadienyl, 9,12-hexadecadienyl, 9,13-hexadecadienyl, 9,14-hexadecadienyl, 9,15-hexadecadienyl, 10,12-hexadecadienyl, 10,13-hexadecadienyl, 10,14-hexadecadienyl, 10,15-hexadecadienyl, 11,13-hexadecadienyl, 11,14-hexadecadienyl, 11,15-hexadecadienyl , 12,14-hexadecadienyl, 12,15-hexadecadienyl, 13,15-hexadecadienyl, 1,3-heptadecadienyl, 1,4-heptadecadienyl, 1,5-heptadecadienyl, 1,6-heptadecadienyl, 1,7-heptadecadienyl, 1,8-heptadecadienyl, 1,9-heptadecadienyl, 110-heptadecadienyl, 111-heptadecadienyl, 112-heptadecadienyl, 113-heptadecadienyl, 114-heptadecadienyl, 115-heptadecadienyl, 116-heptadecadienyl Nyl, 2,4-heptadecadienyl, 2,5-heptadecadienyl, 2,6-heptadecadienyl, 2,7-heptadecadienyl, 2,8-heptadecadienyl, 2,9-heptadecadienyl, 2,10-heptadecadienyl, 2,11-heptadecadienyl, 2,12-heptadecadienyl, 2,13-heptadecadienyl, 2,14-heptadecadienyl, 2,15-heptadecadienyl, 2,16-heptadecadienyl, 3,5-heptadecadienyl, 3,6-heptadecadienyl, 3,7-heptadecadienyl, 3,8-heptadecadienyl, 3,9-heptadecadienyl, 3,10-heptadecadienyl, 3,11-heptadecadienyl, 3,12-heptadecadienyl, 3,13-heptadecadienyl, 3,14-heptadecadienyl, 3,15-heptadecadienyl, 3,16-heptadecadienyl, 4,6-heptadecadienyl, 4,7-heptadecadienyl, 4,8-heptadecadienyl, 4,9-heptadecadienyl, 4,10-heptadecadienyl, 4,11-heptadecadienyl, 4,12-heptadecadienyl, 4,13-heptadecadienyl, 4,14-heptadecadienyl 4,15-heptadecadienyl, 4,16-heptadecadienyl, 5,7-heptadecadienyl, 5,8-heptadecadienyl, 5,9-heptadecadienyl, 5,10-heptadecadienyl, 5,11-heptadecadienyl, 5,12-heptadecadienyl, 5,13-heptadecadienyl, 5,14-heptadecadienyl, 5,15-heptadecadienyl, 5,16-heptadecadienyl, 6,8-heptadecadienyl, 6,9-heptadecadienyl, 6,10-heptadecadienyl, 6,11-heptadecadienyl, 6,12-heptadecadienyl Dienyl, 6,13-heptadecadienyl, 6,14-heptadecadienyl, 6,15-heptadecadienyl, 6,16-heptadecadienyl, 7,9-heptadecadienyl, 7,10-heptadecadienyl, 7,11-heptadecadienyl, 7,12-heptadecadienyl, 7,13-heptadecadienyl, 7,14-heptadecadienyl, 7,15-heptadecadienyl, 7,16-heptadecadienyl, 8,10-heptadecadienyl, 8,11-heptadecadienyl, 8,12-heptadecadienyl, 8,13-heptadecadienyl, 8,1 4-heptadecadienyl, 8,15-heptadecadienyl, 8,16-heptadecadienyl, 9,11-heptadecadienyl, 9,12-heptadecadienyl, 9,13-heptadecadienyl, 9,14-heptadecadienyl, 9,15-heptadecadienyl, 9,16-heptadecadienyl, 10,12-heptadecadienyl, 10,13-heptadecadienyl, 10,14-heptadecadienyl, 10,15-heptadecadienyl, 10,16-heptadecadienyl, 11,13-heptadecadienyl, 11,14-heptadecadienyl, 11,15-Heptadecadienyl, 11,16-Heptadecadienyl, 12,14-Heptadecadienyl, 12,15-Heptadecadienyl, 12,16-Heptadecadienyl, 13,15-Heptadecadienyl, 13,16-Heptadecadienyl, 14,16-Heptadecadienyl, 1,3-Octadecadienyl, 1,4-Octadecadienyl, 1,5-Octadecadienyl, 1,6-Octadecadienyl, 1,7-Octadecadienyl, 1,8-Octadecadienyl, 1,9-Octadecadienyl, 1,10-Octadecadienyl, 1,11-Octadecadienyl Decadienyl, 1,12-octadecadienyl, 1,13-octadecadienyl, 1,14-octadecadienyl, 1,15-octadecadienyl, 1,16-octadecadienyl, 1,17-octadecadienyl, 2,4-octadecadienyl, 2,5-octadecadienyl, 2,6-octadecadienyl, 2,7-octadecadienyl, 2,8-octadecadienyl, 2,9-octadecadienyl, 2,10-octadecadienyl, 2,11-octadecadienyl, 2,12-octadecadienyl, 2,13-octadecadienyl, 2,14-octadecadienyl Octadecadienyl, 2,15-octadecadienyl, 2,16-octadecadienyl, 2,17-octadecadienyl, 3,5-octadecadienyl, 3,6-octadecadienyl, 3,7-octadecadienyl, 3,8-octadecadienyl, 3,9-octadecadienyl, 3,10-octadecadienyl, 3,11-octadecadienyl, 3,12-octadecadienyl, 3,13-octadecadienyl, 3,14-octadecadienyl, 3,15-octadecadienyl, 3,16-octadecadienyl, 3,17-octadecadienyl, 4,6 -Octadecadienyl, 4,7-Octadecadienyl, 4,8-Octadecadienyl, 4,9-Octadecadienyl, 4,10-Octadecadienyl, 4,11-Octadecadienyl, 4,12-Octadecadienyl, 4,13-Octadecadienyl, 4,14-Octadecadienyl, 4,15-Octadecadienyl, 4,16-Octadecadienyl, 4,17-Octadecadienyl, 5,7-Octadecadienyl, 5,8-Octadecadienyl, 5,9-Octadecadienyl, 5,10-Octadecadienyl, 5,11-Octadecadienyl, 5,12-Octadecadienyl, 5,13-Octadecadienyl, 5,14-Octadecadienyl, 5,15-Octadecadienyl, 5,16-Octadecadienyl, 5,17-Octadecadienyl, 6,8-Octadecadienyl, 6,9-Octadecadienyl, 6,10-Octadecadienyl, 6,11-Octadecadienyl, 6,12-Octadecadienyl, 6,13-Octadecadienyl, 6,14-Octadecadienyl, 6,15-Octadecadienyl, 6,16-Octadecadienyl, 6,17-Octadecadienyl Lu, 7,9-octadecadienyl, 7,10-octadecadienyl, 7,11-octadecadienyl, 7,12-octadecadienyl, 7,13-octadecadienyl, 7,14-octadecadienyl, 7,15-octadecadienyl, 7,16-octadecadienyl, 7,17-octadecadienyl, 8,10-octadecadienyl, 8,11-octadecadienyl, 8,12-octadecadienyl, 8,13-octadecadienyl, 8,14-octadecadienyl, 8,15-octadecadienyl, 8,16-octadecadienyl Decadienyl, 8,17-octadecadienyl, 9,11-octadecadienyl, 9,12-octadecadienyl, 9,13-octadecadienyl, 9,14-octadecadienyl, 9,15-octadecadienyl, 9,16-octadecadienyl, 9,17-octadecadienyl, 10,12-octadecadienyl, 10,13-octadecadienyl, 10,14-octadecadienyl, 10,15-octadecadienyl, 10,16-octadecadienyl, 10,17-octadecadienyl, 11,13-octadecadienyl It includes dienyl, 11,14-octadecadienyl, 11,15-octadecadienyl, 11,16-octadecadienyl, 11,17-octadecadienyl, 12,14-octadecadienyl, 12,15-octadecadienyl, 12,16-octadecadienyl, 12,17-octadecadienyl, 13,15-octadecadienyl, 13,16-octadecadienyl, 13,17-octadecadienyl, 14,16-octadecadienyl, 14,17-octadecadienyl, and 15,17-octadecadienyl.

[0049] As used herein, the term “pharmaceutically acceptable” means suitable for use in a subject, e.g., a mammal, e.g., a human.

[0050] Examples of pharmaceutically acceptable counteranions of this disclosure include, but are not limited to, chloride ions, bromide ions, fluoride ions, iodide ions, nitrate ions, sulfate ions, methyl sulfate ions, phosphate ions, acetate ions, benzoate ions, citrate ions, glutamate ions, and lactate ions.

[0051] Examples of pharmaceutically acceptable salts of the present disclosure include, but are not limited to, salts containing chloride ions, bromide ions, fluoride ions, iodide ions, nitrate ions, sulfate ions, methyl sulfate ions, phosphate ions, acetate ions, benzoate ions, citrate ions, glutamate ions, and / or lactate ions. pharmaceutically acceptable salts of the compounds of formula I of the present disclosure can be synthesized by conventional chemical methods. For example, salts of the compounds can be prepared by ion-exchange chromatography or by reacting the free base in the compound with a stoichiometric amount or excess of a desired salt-forming inorganic or organic acid in a suitable solvent or a variety of solvent combinations.

[0052] Generally, compounds may contain one or more chiral centers. Compounds containing one or more chiral centers may include those described as "isomers," "stereoisomers," "diastereomers," "enantiomers," "optical isomers," or "racemic mixtures." Conventions of stereochemical nomenclature, such as the stereoisomer nomenclature rules of Kahn, Ingold, and Prelogue, as well as methods for determining stereochemistry and separating stereoisomers, are known in the art. See, for example, Michael B. Smith and Jerry March, March's Advanced Organic Chemistry, 5th edition, 2001. The compounds and structures of this disclosure, including chemical drawings, are intended to encompass all possible isomers, chemically reasonable regioisomers, stereoisomers, diastereomers, enantiomers, and / or optical isomers (including racemates or any other mixture thereof) that would be understood to exist for any identified compound or structure.

[0053] The compounds of formula I of this disclosure can be prepared by at least one of the techniques described herein or known organic synthesis techniques.

[0054] For example, the compound of formula I can be obtained as shown in scheme I below. In scheme I, the variable elements n, m, and A 1 , A 2 , A 3 , A 4 , and A 5The definition of is the same as the definition for formula I described herein. Compound a1 may react with compound a2 to yield compound a3. Step 1 can be carried out in an organic solvent (e.g., methylene chloride) in the presence of, for example, EDC·HCl and DMAP. Step 1 can be carried out at 0°C to 50°C for 1 to 24 hours. Compound a4 may react with compound a5 to yield compound a6. Other acid-unstable protecting groups can be used instead of the Boc group in compound a5. Step 2 can be carried out in an organic solvent (e.g., methylene chloride) in the presence of, for example, EDC·HCl, triethylamine and DMAP. Step 2 can be carried out at 0°C to 50°C for 1 to 24 hours. The Boc group of compound a6 may be deprotected to yield compound a7. Step 3 can be carried out in an organic solvent (e.g., methylene chloride) in the presence of an acid (e.g., methanesulfonic acid). Step 3 can be carried out at 0°C to 50°C for 1 to 24 hours. Compound a7 may react with compound a3 to yield compound a8. Step 4 can be carried out in an organic solvent (e.g., acetonitrile, cyclopropyl methyl ether, or a mixture thereof) in the presence of a base (e.g., potassium carbonate). KI may be added to accelerate the reaction. Step 4 can be carried out at 0°C to 100°C for 1 to 24 hours. Compound a8 may react with compound a9 to yield the compound of formula I. Step 5 can be carried out in an organic solvent (e.g., methylene chloride) in the presence of a combination of EDC·HCl, triethylamine, and DMAP, or a combination of HATU and triethylamine. Step 5 can be carried out at 0°C to 50°C for 1 to 24 hours.

[0055] [ka]

[0056] The compound of formula I can also be obtained as shown in scheme II below. In scheme II, the variable elements n, m, p1, p2, R 1 , R 2 , R 3 , R4 , A 1 , A 2 , A 3 , A 4 , and A 5 have the same definitions as those defined for Formula I described in the present specification. Compound a8, which can be prepared according to Scheme I, may react with compound b1 to yield compound b2. Step 1 can be carried out in an organic solvent (e.g., methylene chloride) in the presence of a base, such as triethylamine. Step 1 can be performed at 0°C to 50°C for 5 minutes to 24 hours. Compound b2 may react with compound b3 to yield the compound of Formula I. Step 2 can be carried out in an organic solvent (e.g., acetonitrile, THF, or a mixed solvent thereof) in the presence of a base, such as DBU. Step 2 can be performed at 0°C to 100°C for 1 hour to 24 hours.

[0057]

Chemical Formula

[0058] The compound of Formula I can also be obtained as shown in Scheme III. In Scheme III, the variables n, m, A 1 , A 2 , A 3 , A 4 , and A 5The definition of is the same as the definition for formula I described herein. Compound a3, which can be prepared according to scheme I, can react with compound c1. Step 1 can be carried out in an organic solvent (e.g., acetonitrile, cyclopropyl methyl ether, or a mixture thereof) in the presence of a base (e.g., potassium carbonate). Step 1 can be carried out at 0°C to 100°C for 1 to 24 hours. The product resulting from Step 1 may react with Boc2O to yield compound c1. Step 2 can be carried out in an organic solvent (e.g., methylene chloride) in the presence of a base (e.g., triethylamine). Step 2 can be carried out at 0°C to 50°C for 1 to 24 hours. Other acid-unstable protecting groups can be used instead of the Boc group in compound c1. Compound c1 can react with compound c2. Step 3 can be carried out in an organic solvent (e.g., methylene chloride) in the presence of a base (e.g., triethylamine). Step 3 can be carried out at 0°C to 50°C for 10 minutes to 24 hours. The product resulting from step 3 can be deprotected to yield compound c3. Step 4 can be carried out in an organic solvent (e.g., methylene chloride) in the presence of an acid (e.g., methanesulfonic acid). Step 4 can be carried out at 0°C to 50°C for 1 to 24 hours. Step 5 can be carried out according to the procedure of step 5 in scheme I, or steps 1 and 2 in scheme II.

[0059] [ka]

[0060] Compound A of formula I 1 If the reaction contains a tertiary amine, the amine can be alkylated with an alkylating agent (e.g., MeI). The reaction can be carried out at 0°C to 50°C for 1 to 24 hours.

[0061] Pharmaceutical composition Some embodiments of this disclosure are as follows: Lipid nanoparticles, and Pharmaceutical active ingredients encapsulated in lipid nanoparticles The present invention relates to a pharmaceutical composition comprising lipid nanoparticles, wherein the lipid nanoparticles comprise a compound of formula I as described elsewhere in this specification or a pharmaceutically acceptable salt thereof.

[0062] As used herein, the term “lipid nanoparticles” (also known as “LNPs” or “liposomes”) refers to nanoparticles containing lipid molecules.

[0063] As used herein, the term “encapsulate” refers to the ability of a nanoparticle to hold a pharmacokinetic ingredient within its structure or on its surface so that the pharmacokinetic ingredient is not removed by a solvent or mobile phase outside the particle.

[0064] The term "lipid" is used herein to encompass substances that are soluble in organic solvents but sparingly soluble in water (sparing soluble) or insoluble.

[0065] The “ionizable cationic lipids” of this disclosure are characterized by the weak basicity of their lipid head groups, which affects the surface charge of the lipid in a pH-dependent manner, positively charging it at acidic pH but nearly neutral at physiological pH. In some embodiments, the compounds of formula I of this disclosure are ionizable cationic lipids. The “cationic lipids” of this disclosure are characterized by a monovalent or polyvalent cationic charge on their head groups, which positively charges them at neutral pH. In some embodiments, the compounds of formula I of this disclosure are cationic lipids. In certain embodiments, cationic lipids and ionizable cationic lipids can form complexes with hydrophilic bioactive molecules to generate hydrophobic complexes that partition into the organic phase of a two-phase water / organic system. It is intended that both monovalent and polyvalent cationic lipids can be used to form hydrophobic complexes with bioactive molecules.

[0066] In some embodiments, the lipid nanoparticles include structural lipids such as sterol lipids. In some embodiments, the structural lipids are sterol lipids such as beta-sitosterol, stigmasterol, ergosterol, ergocalciferol, cholesterol, or derivatives thereof.

[0067] In some embodiments, the lipid nanoparticles contain stabilizer lipids such as phospholipids. In some embodiments, the stabilizer lipids are phospholipids such as diphytanoylphosphatidylethanolamine (DPhPE) and 1,2-dphytanoyl-sn-glycero-3-phosphocholine (DPhPC). Examples of stabilizer lipids include 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine (DPPE), and 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE).

[0068] In some embodiments, the lipid nanoparticles include lipids to reduce immunogenicity, such as pegylated lipids. The PEG region of the pegylated lipid can have any molecular weight. In some embodiments, the PEG region may have molecular weights of 200, 300, 350, 400, 500, 550, 750, 1000, 1500, 2000, 3000, 3500, 4000, or 5000 Da. In some embodiments, the pegylated lipids include DSPE-PEG, DMPE-PEG, DPPE-PEG, DOPE-PEG, and DMG-PEG.

[0069] In some embodiments, the lipid nanoparticles contain 40-60 mol% of a compound of formula I as described elsewhere herein or a pharmaceutically acceptable salt thereof; 30-50 mol% of sterol lipids relative to the total lipid content of the lipid nanoparticles; 5-15 mol% of phospholipids selected from the group consisting of DSPC, DOPC, and DOPE relative to the total lipid content of the lipid nanoparticles; and 1-5 mol% of DMG-PEG, a lipid for reducing immunogenicity, relative to the total lipid content of the lipid nanoparticles. The molar ratio (compound of formula I or a pharmaceutically acceptable salt thereof / sterol lipid / phospholipid / DMG-PEG) in the lipid nanoparticles according to this disclosure is not limited to the following, but includes (60 / 31 / 8 / 1), (60 / 31 / 7.5 / 1.5), (60 / 31 / 7 / 2) (60 / 31 / 6.5 / 2.5), (60 / 31 / 6 / 3), (60 / 31 / 5.5 / 3.5), (60 / 31 / 5 / 4), (60 / 31 / 4.5 / 4.5), (60 / 31 / 4 / 5), (60 / 31.5 / 7.5 / 1), (60 / 30.5 / 7.5 / 2), (60 / 30 / 7.5 / 2.5), (60 / 29.5 / 7.5 / 3), (60 / 29 / 7.5 / 3.5), (60 / 28.5 / 7.5 / 4), (60 / 28 / 7.5 / 4.5), (60 / 27.5 / 7.5 / 5), (59 / 32 / 7.5 / 1.5), (58 / 33 / 7.5 / 1.5), (57 / 34 / 7.5 / 1.5), (56 / 35 / 7.5 / 1.5), (55 / 36 / 7.5 / 1.5), (60 / 29 / 10 / 1), (60 / 28.5 / 10 / 1.5), (60 / 28 / 10 / 2), (60 / 27.5 / 10 / 2. 5), (60 / 27 / 10 / 3), (60 / 26.5 / 10 / 3.5), (60 / 26 / 10 / 4), (60 / 25.5 / 10 / 4.5), (60 / 25 / 10 / 5), (60 / 27 / 12 / 1), (60 / 27 / 11.5 / 1.5), (60 / 27 / 11 / 2), (60 / 27 / 10.5 / 2.5), (60 / 27 / 9.5 / 3.5), (60 / 27 / 9 / 4), (60 / 27 / 8.5 / 4.5), (60 / 27 / 8 / 5), (59 / 28 / 10 / 3), (58 / 29 / 10 / 3), (57 / 30 / 10 / 3), (56 / 31 / 10 / 3), (55 / 32 / 10 / 3), (50 / 39 / 10 / 1), (50 / 38.5 / 10 / 1.5), (50 / 38 / 10 / 2), (50 / 37.5 / 10 / 2.5), (50 / 37 / 10 / 3), (50 / 36.5 / 10 / 3.5), (50 / 36 / 10 / 4), (50 / 35.5 / 10 / 4.5), (50 / 35 / 1 0 / 5), (50 / 38.5 / 10.5 / 1), (50 / 38.5 / 9.5 / 2), (50 / 38.5 / 9 / 2.5), (50 / 38.5 / 8.5 / 3), (50 / 38.5 / 8 / 3.5), (50 / 38.5 / 7.5 / 4), (50 / 38.5 / 7 / 4.5), (50 / 38.5 / 6.5 / 5), (51 / 37.5 / 10 / 1.5), (52 / 36.5 / 10 / 1.5), (53 / 35.5 / 10 / 1.5), (54 / 34.5 / 10 / 1.5), (55 / 33. 5 / 10 / 1.5), (49 / 39.5 / 10 / 1.5), (48 / 40.5 / 10 / 1.5), (47 / 41.5 / 10 / 1.5), (46 / 42.5 / 10 / 1.5), (45 / 43.5 / 10 / 1.5), (51 / 34 / 10 / 5), (52 / 33 / 10 / 5), (53 / 32 / 10 / 5), (54 / 31 / 10 / 5), (55 / 30 / 10 / 5), (40 / 44 / 15 / 1), (40 / 43.5 / 15 / 1.5), (40 / 43 / 15 / 2), (40 / 42 Examples include (0.5 / 15 / 2.5), (40 / 42 / 15 / 3), (40 / 41.5 / 15 / 3.5), (40 / 41 / 15 / 4), (40 / 40.5 / 15 / 4.5), (40 / 40 / 15 / 5), (41 / 39 / 15 / 5), (42 / 38 / 15 / 5), (43 / 37 / 15 / 5), (44 / 36 / 15 / 5), (45 / 35 / 15 / 5), (41 / 41 / 14 / 4), (42 / 42 / 13 / 3), (43 / 43 / 12 / 2), and (44 / 44 / 11 / 1).

[0070] In some embodiments, the lipid nanoparticles include a cationic lipid and / or an ionizable cationic lipid in addition to the compound of formula I.

[0071] In some embodiments, the average particle size of the lipid nanoparticles is 50–250 nm (e.g., 50–200 nm, 50–175 nm, or 50–150 nm). In some embodiments, the polydispersity index (PDI) of the lipid nanoparticles is less than 0.2. The average particle size and PDI of the LNPs can be evaluated by dynamic light scattering (DLS).

[0072] In some embodiments, the active pharmaceutical ingredient includes nucleic acids. In some embodiments, the nucleic acids include interfering RNA molecules, such as siRNA, aiRNA, miRNA, or mixtures thereof. In certain other cases, the nucleic acids include single-stranded or double-stranded DNA, RNA, or DNA / RNA hybrids, such as antisense oligonucleotides, ribozymes, plasmids, immunostimulatory oligonucleotides, or mixtures thereof. In certain cases, the nucleic acids include mRNA molecules.

[0073] In some embodiments, the pharmaceutical composition includes a pharmaceutically acceptable carrier. As used herein, a “pharmaceutically acceptable carrier” (also called “excipient”) is a pharmaceutically acceptable solvent, suspending agent, or any other pharmaceutically inert vehicle. The pharmaceutically acceptable carrier may be liquid or solid and can be selected with the planned mode of administration in mind to provide the desired bulk, stiffness, and other suitable transport and chemical properties. Typical pharmaceutically acceptable carriers include, but are not limited to, water, saline solution, binders (e.g., polyvinylpyrrolidone or hydroxypropyl methylcellulose), fillers (e.g., lactose and other sugars, gelatin, or calcium sulfate), lubricants (e.g., starch, polyethylene glycol, or sodium acetate), disintegrants (e.g., starch or sodium starch glycolate), and wetting agents (e.g., sodium lauryl sulfate).

[0074] Pharmaceutical compositions can be prepared in various forms suitable for various routes and methods of administration. For example, pharmaceutical compositions can be prepared in liquid dosage forms (e.g., emulsions, microemulsions, nanoemulsions, solutions, suspensions, syrups, and elixirs), injectable forms, solid dosage forms (e.g., capsules, tablets, pills, powders, and granules), topical and / or transdermal dosage forms (e.g., ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants, and patches), suspensions, powders, and other forms.

[0075] The lipid nanoparticles of this disclosure can be synthesized by any suitable process, including adaptation of processes known in the art, and loaded into encapsulated cargoes. In some embodiments, the lipid nanoparticles can be prepared by an immersion injection process. Some examples of processes for preparing lipid nanoparticles are shown in U.S. Publication No. 2013 / 0115274. Some examples for preparing liposomes are shown in Szoka, Ann. Rev. Biophys. Bioeng. 9:467 (1980); Liposomes, Marc J. Ostro, ed., Marcel Dekker, Inc., New York, 1983, Chapter 1. Generally, lipid nanoparticles can be synthesized by mixing lipid components in an organic solvent with an aqueous buffer solution containing an active nucleic acid agent. Liposomes can be made to a predetermined size by filtration or extrusion. The liposome suspension or solution may be further modified by diafiltration. In some embodiments, lipid nanoparticles can be synthesized by injecting an ethanol solution of lipids into a buffer solution containing the active pharmaceutical ingredient, in the same manner as described in U.S. Publication No. 2013-0022665, PCT Publication No. WO2019 / 090359, and PCT Publication No. WO2020 / 102668. In some embodiments, lipid nanoparticles can be synthesized by combining the lipid solution with the active pharmaceutical ingredient solution using a microfluidic mixing device such as NanoAssemblr® (Precision Nano Systems).

[0076] Methods for delivering active pharmaceutical ingredients to cells or targets Some embodiments of this disclosure relate to a method for delivering a pharmaceutical active ingredient to cells, comprising the step of bringing a pharmaceutical composition described herein into contact with the cells. In certain embodiments, the cells are in vitro. In certain embodiments, the cells are in vivo. In certain embodiments, the cells are ex vivo.

[0077] Some embodiments of this disclosure relate to methods for delivering a pharmacokinetic active ingredient to a subject requiring delivery of the pharmacokinetic active ingredient, comprising the step of administering the above-described pharmaceutical composition to the subject. For example, the pharmacokinetic active ingredient may be an siRNA effective for knockdown of the GSTp gene, as described in Example 22 below. Subjects include, but are not limited to, mammals such as humans, monkeys, rats, and mice. The pharmaceutical composition may be administered by any means known in the art, including, but not limited to, oral or parenteral routes, including intravenous, intramuscular, subcutaneous, transdermal, or respiratory (aerosol) administration. [Examples]

[0078] TIFF0007954317000026.tif81144

[0079] Example 1: Synthesis of Compound 1 (Heptadecan-9-yl-8-(2-(dimethylamino)-N-(6-oxo-6-(undecyloxy)hexyl)acetamide)octanoate) from Table 1 Compound 1 was prepared according to Scheme 1 shown in Figure 1.

[0080] Step 1: To a solution of heptadecane-9-ol (2 g, 7.7 mmol, 1 eq.) and 8-bromooctanoic acid (2.2 g, 10 mmol, 1.3 eq.) in anhydrous methylene chloride (DCM, 40 ml), EDC·HCl (1.8 g, 9.7 mmol, 1.25 eq.) and DMAP (95 mg, 0.77 mmol, 0.1 eq.) were added. The clear solution was stirred overnight (18 hours) at room temperature. The next day, the reaction was stopped and diluted with DCM. The organic matter was sequentially washed with saturated sodium bicarbonate solution (25 mL), water (25 mL), and brine (25 mL). The separated organic phase was dried over sodium sulfate and filtered. The organic phase was concentrated, and the crude product was purified by ISCO MPLC using a silica gel column (80 g), and the column was eluted with a (0-20)% hexane-ethyl acetate gradient. The fractions were combined and concentrated to obtain intermediate 1 (2.7 g, yield 75%) as an oily substance.

[0081] Step 2: To a solution of undecane-1-ol (8 g, 46.4 mmol, 1 eq.) and 6-N-Boc-aminohexanoic acid (12.8 g, 55.7 mmol, 1.2 eq.) in anhydrous DCM (150 ml), EDC·HCl (10.6 g, 55.7 mmol, 1.2 eq.), triethylamine (12.9 mL, 92.8 mmol), and DMAP (0.5 g, 4.64 mmol, 0.1 eq.) were added. The clear reaction solution was stirred overnight at room temperature under N2 gas. IPC (LC / MS) showed the corresponding product peak (m / z = 385 (M+H)) with saturated sodium bicarbonate solution (50 mL) and brine (50 mL). The organic phase was dried over sodium sulfate, filtered, and the solvent was evaporated using a rotary evaporator to obtain the crude product. 5 g of the crude product was removed for the next reaction, and the remaining material was dissolved in anhydrous DCM (100 mL). Et3N and Boc2O were added to the above solution and stirred overnight. Complete conversion of de-Boc amine to the desired Boc-amine product was confirmed by LC / MS. The organic layer was washed with water and brine solution. The organic phase was dried over Na2SO4 and filtered. The organic phase was concentrated, and the crude product was purified by ISCO MPLC using a silica gel column (220 g), and the column was eluted with a (0-100)% hexane-ethyl acetate gradient. The fractions were combined and concentrated to obtain intermediate 2 (12.5 g) as an oily substance. The obtained product was stored in a freezer and formed as a white solid.

[0082] Step 3: Intermediate 2 (3.4 g, 8.8 mmol) was dissolved in DCM (40 mL), and methanesulfonic acid (1.2 mL, 20.7 mmol, 2 eq) was added. The clear solution was stirred overnight at room temperature. The following day, LC / MS confirmed the complete conversion of the starting material to the product. The reaction mixture was diluted with DCM (25 mL) and washed with saturated sodium bicarbonate solution (25 mL). The organic phase was dried over Na2SO4 and filtered. The organic phase was concentrated and dried to obtain free amine intermediate 3 in quantitative yield. This material was used in the next step without further purification.

[0083] Step 4: Solutions of intermediate 1 (1.8 g, 3.8 mmol, 1 eq.) and intermediate 3 (2.2 g, 7.6 mmol, 2 eq.) in a mixture of acetonitrile / cyclopropyl methyl ether (40 mL, 1:1) were treated with potassium carbonate (134 mg, 10.8 mmol, 2 eq.) under N2 gas. The reaction flask was heated at 72–75°C for 5 hours. LC / MS showed the formation of the desired peak, along with a small peak corresponding to the dialkylation byproduct. The reaction mixture was cooled to room temperature, filtered through a Celite pad, and washed with DCM (20 mL). The resulting product was concentrated and purified by an ISCO MPLC system using a silica column (80 g). The column was eluted with a (0–20)% DCM / MeOH gradient. The fractions were combined and concentrated under reduced pressure using a rotary evaporator to obtain intermediate 4 (2.2 g, 84% yield) as a solid.

[0084] Step 5: The solution of intermediate 4 (2.2 g, 3.3 mmol, 1 eq) in anhydrous DCM (30 mL) was stirred and cooled to 0°C. Chloroacetyl chloride (0.26 mL, 3.3 mmol, 1 eq) was added, followed by the slow addition of Et3N (1.3 mL, 9.9 mL). After 10 minutes, LC / MS confirmed that the reaction was complete. The reaction mixture was diluted with DCM (25 mL) and washed with saturated NaHCO3 solution (25 mL) and brine (25 mL). The organic phase was dried over Na2SO4 and filtered. The organic phase was concentrated and purified by ISCO MPLC using a silica gel column (80 g), and the column was eluted with a (0-50)% hexane / ethyl acetate gradient. The fractions were combined and concentrated under reduced pressure using a rotary evaporator to obtain intermediate 5 (2.0 g, yield 83%) as an oil.

[0085] Step 6: To a solution of intermediate 5 (1 g, 1.3 mmol, 1 eq) in LC / MS grade acetonitrile (20 mL), dimethylamine (3.3 mL, 6.7 mmol, 5 eq, 2 M in THF) and DBU (0.4 mL, 2.6 mmol, 2 eq) were sequentially added under N2 gas. The clear solution was stirred overnight at room temperature. The next day, complete conversion to the product was confirmed by LC / MS. The reaction mixture was concentrated under reduced pressure, diluted with DCM (55 mL), and washed with saturated NaHCO3 solution (25 mL) and brine (25 mL). The organic phase was dried over Na2SO4 and filtered. The organic phase was concentrated, and the crude product was purified by MPLC / ISCO using a silica column (40 g). The column was eluted with a (0-100)% hexane-siRNA and a (0-20)% DCM-MeOH gradient. The fractions were combined and concentrated using a rotary evaporator to obtain compound 1 (720 mg, 71% yield) as an oil. ESI MS (m / z): 751.74 (M+H) + .

[0086] Example 2: Synthesis of Compound 2 (2-((8-(heptadecane-9-yloxy)-8-oxooctyl)(6-oxo-6-(undecyloxy)hexyl)amino)-N,N,N-trimethyl-2-oxoethane-1-aminium chloride) from Table 1 Compound 2 was prepared according to Scheme 2 shown in Figure 2.

[0087] Compound 1 (210 mg, 0.27 mmol, 1 eq) was placed in a 15 mL scintillation vial, and MeI (1.5 mL, excess) was added. The resulting clear solution was stirred at room temperature overnight. The next day, LC / MS indicated that the starting material was completely converted to the methyl salt. Excess MeI was evaporated, and the intermediate was purified by ISCO MPLC using a 25 g silica column. The column was eluted with a (0 to 20)% DCM-MeOH gradient. Pure fractions were concentrated to afford the intermediate with iodide as the counterion. This material was dissolved in DCM (4 mL) and passed through a column of Amberlyst A26 (5.5 g, activated with HCl). The column was eluted with 100% DCM, and all fractions were concentrated. The resulting residue was redissolved in a minimal volume of DCM and passed through the above column. The column was eluted again with DCM, and all fractions were concentrated. The product was dried under high vacuum to afford Compound 2 (130 mg, 60% yield) with chloride as the counterion. ESI MS (m / z): 765.85 (M) + .

[0088] Example 3: Synthesis of Compound 3 in Table 1 (heptadecan-9-yl 8-(2-((2-(dimethylamino)ethyl)thio)-N-(6-oxo-6-(undecyloxy)hexyl)acetamido)octanoate) Compound 3 was prepared according to Scheme 3 shown in Figure 3.

[0089] Step 5: Steps 1-4 of Scheme 3 were carried out in the same manner as described in Steps 1-4 of Scheme 1 above. To a mixture of Intermediate 4 (800 mg, 1.2 mmol, 1 eq) in anhydrous DCM (20 mL) and {(2-dimethylamino)ethylthio}acetic acid (391 mg, 2.4 mmol, 2 eq) in DCM (20 mL), Et3N (0.33 mL, 2.4 mmol), DMAP (14 mg, 0.12 mmol, 0.1 eq), and EDC.HCl (287 mg, 1.56 mmol, 1.2 eq) were sequentially added at room temperature under N2 gas. The resulting mixture was stirred overnight at room temperature. The next day, product formation was confirmed by LC / MS. The reaction mixture was diluted with DCM (30 mL) and washed with saturated NaHCO3 aqueous solution (20 mL) and brine (20 mL). The organic phase was dried over Na2SO4 and filtered. The organic phase was concentrated and purified by ISCO MPLC using a silica gel column (40 g). The column was eluted using a (0-100)% hexane / ethyl acetate and (0-20%) DCM-MeOH gradient. The fractions were combined and concentrated under reduced pressure using a rotary evaporator to obtain compound 3 (405 mg, 43% yield) as an oil. ESI MS (m / z): 811.71 (M+H) + .

[0090] Example 4: Synthesis of Compound 4 (2-((2-((8-(heptadecan-9-yloxy)-8-oxooctyl)(6-oxo-6-(undecyloxy)hexyl)amino)-2-oxoethyl)thio)-N,N,N-trimethylethane-1-aminium chloride) from Table 1 Compound 4 was prepared according to Scheme 4 shown in Figure 4.

[0091] Compound 3 (120 mg, 0.14 mmol, 1 eq) was weighed in a 15 mL scintillation vial, and then MeI (1.5 mL, excess) was added. The resulting clear solution was stirred overnight at room temperature. The following day, LC / MS showed the corresponding product peak, along with another peak corresponding to m / z=834. The excess MeI was evaporated, and the intermediate was purified by ISCO MPLC using a 25 g silica column. The column was eluted with a (0-20)% DCM-MeOH gradient. The pure fraction was concentrated to obtain the intermediate as an iodide counterion. This intermediate was dissolved in DCM (4 mL) and passed through an Amberlyst A26 (5 g, activated with HCl) column. The column was eluted with 100% DCM, and the entire fraction was concentrated. The resulting residue was again dissolved in the minimum volume of DCM and passed through the same column. The column was eluted again with DCM, and the entire fraction was concentrated. The product was dried under high vacuum to obtain the desired product, compound 4 (82 mg, 67% yield), as a chloride counterion. ESI MS (m / z): 825.78 (M) + .

[0092] Example 5: Synthesis of Compound 5 (Heptadecan-9-yl8-(2-(cis-3,4-dihydroxypyrrolidine-1-yl)-N-(6-oxo-6-(undecyloxy)hexyl)acetamide)octanoate) from Table 1 Compound 5 was prepared according to Scheme 5 shown in Figure 5.

[0093] Step 6: Steps 1-5 of Scheme 5 were carried out in the same manner as described in Steps 1-5 of Scheme 1 above. Intermediate 5 (600 mg, 0.81 mmol, 1 eq) and cis-DHP.HCl (225 mg, 1.6 mmol, 2 eq) were suspended in LC / MS grade acetonitrile (40 mL). DBU (0.23 mL, 1.6 mmol, 2 eq) was added, and the reaction flask was heated to 45 °C and stirred overnight under N2 gas. The following day, complete conversion to the product was confirmed by LC / MS. The heating bath was removed and the reaction flask was cooled to room temperature. The reaction mixture was concentrated under reduced pressure using a rotary evaporator, and the crude product was purified by MPLC / ISCO using a silica column (40 g). The column was eluted with a (0-100)% hexane-siRNA and a (0-20)% DCM-MeOH gradient. The fractions were combined and concentrated using a rotary evaporator to obtain compound 5 (455 mg, 70% yield) as an oil. ESI MS (m / z): 809.72 (M+H) + .

[0094] Example 6: Synthesis of compound 6 (1-(2-((8-(heptadecan-9-yloxy)-8-oxooctyl)(6-oxo-6-(undecyloxy)hexyl)amino)-2-oxoethyl)-cis-3,4-dihydroxy-1-methylpyrrolidine-1-ium chloride) from Table 1 Compound 6 was prepared according to scheme 6 shown in Figure 6.

[0095] Compound 5 (120 mg, 0.14 mmol, 1 eq) was placed in a 15 mL scintillation vial, and MeI (1.3 mL, excess) was added. The resulting clear solution was stirred overnight at room temperature. The next day, LC / MS showed that the starting material had been completely converted to the methyl iodide salt. The excess MeI was evaporated, and the residue was dissolved in DCM (4 mL). This solution was passed through an Amberlyst A26 (5 g, activated with HCl) column. The column was eluted with 100% DCM, and the entire fraction was concentrated. The resulting residue was again dissolved in the minimum volume of DCM and passed through the same column. The column was again eluted with DCM, and the entire fraction was concentrated. The product was dried under high vacuum to obtain compound 6 (116 mg, 89% yield) as a chloride counterion. ESI MS (m / z): 823.73 (M) + .

[0096] Example 7: Synthesis of Compound 7 (Heptadecan-9-yl-8-(2-((2-hydroxyethyl)(methyl)amino)-N-(6-oxo-6-(undecyloxy)hexyl)acetamide)octanoate) from Table 1 Compound 7 was prepared according to Scheme 7 shown in Figure 7.

[0097] Step 6: Steps 1-5 of Scheme 7 were carried out in the same manner as described in Steps 1-4 of Scheme 1 above. A mixture of intermediate 5 (450 mg, 0.60 mmol, 1 eq) and N-methyl N-hydroxyethylamine (91 mg, 1.21 mmol, 2 eq) in LC / MS grade acetonitrile (20 mL) was mixed with DBU (0.17 mL, 1.2 mmol, 2 eq) under N2 gas. The clear solution was stirred overnight at room temperature. The following day, complete conversion to the product was confirmed by LC / MS. The product was concentrated under reduced pressure, diluted with DCM (40 mL), and washed with saturated NaHCO3 solution (2 mL) and brine (20 mL). The organic phase was dried over Na2SO4 and filtered. The organic phase was concentrated, and the crude product was purified by MPLC / ISCO using a silica column (40 g). The column was eluted using a (0-100)% hexane-siRNA and a (0-20)% DCM-MeOH gradient. The fractions were combined and concentrated using a rotary evaporator to obtain compound 7 (204 mg, 43% yield) as an oil. ESI MS (m / z): 781.77 (M+H) + .

[0098] Example 8: Synthesis of Compound 8 (2-(2-(dimethylamino)-N-(8-(heptadecan-9-yloxy)-8-oxooctyl)acetamide)ethyltetradecanoate) from Table 1 Compound 8 was prepared according to scheme 8 shown in Figure 8.

[0099] Step 1: To a stirred solution of heptadecane-9-ol (10 g, 38.9 mmol, 1 eq.) and 8-bromooctanoic acid (10.4 g, 46.7 mmol, 1.2 eq.) in DCM (100 mL), triethylamine (10.8 mL, 77.9 mmol, 2 eq.), DMAP (470 mg, 3.89 mmol, 0.1 eq.), and EDC·HCl (8.9 g, 46.7 mmol, 1.2 eq.) were added. The clear reaction solution was stirred at room temperature under nitrogen gas for 5 hours. The reaction mixture was diluted with DCM (50 mL) and then washed with saturated sodium bicarbonate solution (70 mL), water (50 mL), and brine (50 mL). The organic phase was dried over sodium sulfate and filtered. The organic phase was concentrated, and the crude product was purified by ISCO / MPLC using a silica gel column (220 g). The column was eluted with a (0-30)% hexane-ethyl acetate gradient. The fractions were combined and concentrated under reduced pressure using a rotary evaporator to obtain intermediate 1 (11 g, 61% yield).

[0100] Step 2: Intermediate 1 (6 g, 12.9 mmol, 1 eq.) and aminoethanol (5.9 g, 97.4 mmol, 7.5 eq.) were suspended in an acetonitrile / CPME mixture (60 mL, 1:1). K2CO3 (1.8 g, 12.9 mmol, 1 eq.) was added to the mixture. The reaction mixture was heated to 70°C and stirred for 3 hours. LC / MS confirmed that the reaction was complete. The heating bath was removed and the reaction mixture was cooled to room temperature. The solid was filtered and washed with acetonitrile. The filtrate was concentrated and the residue was suspended in DCM (50 5 L). The organic layer was washed with saturated NaHCO3 aqueous solution (25 mL), water (25 mL), and brine (20 mL). The organic phase was dried over Na2SO4 and filtered. The organic phase was concentrated to obtain the mono-N-alkylation product in quantitative yield. This intermediate was dissolved in DCM (50 mL), and then triethylamine (3.6 mL, 25.8 mmol, 2 eq.) and Boc2O (3.1 g, 14.1 mmol, 1.1 eq.) were added. The mixture was stirred overnight at room temperature. The next day, LC / MS showed that the reaction was complete. The reaction mixture was diluted in DCM (30 mL) and then washed with saturated sodium bicarbonate solution (40 mL) and brine (40 mL). The organic phase was dried over sodium sulfate and filtered. The organic phase was concentrated, and the crude product was purified by ISCO / MPLC using a silica gel column (120 g). The column was eluted with a (0-100)% hexane-ethyl acetate gradient. The fractions were combined and concentrated under reduced pressure using a rotary evaporator to obtain intermediate 2 (4.6 g, yield 66.6%) as an oil.

[0101] Step 3: To a solution of intermediate 2 (2.1 g, 3.8 mmol, 1 eq.) in anhydrous DCM (25 ml), Et3N (1.0 mL, 7.7 mmol, 2 eq.) and myristoyl chloride (1.16 mL, 4.2 mmol, 1.1 eq.) were added at room temperature. After 2 hours, LC / MS confirmed that the reaction was complete. The reaction was stopped and diluted with DCM (20 mL). The organic matter was sequentially washed with saturated sodium bicarbonate solution (20 mL), water (20 mL), and brine solution (20 mL). The organic phase was dried over sodium sulfate and filtered. The organic phase was concentrated, and the crude product was purified by ISCO / MPLC using a silica gel column (80 g), and the column was eluted with a (0-50)% hexane-ethyl acetate gradient. The fractions were combined and concentrated under reduced pressure using a rotary evaporator to obtain intermediate 3 (2.2 g, 76% yield) as an oily substance.

[0102] Step 4: To a solution of intermediate 3 (1.7 g, 2.2 mmol, 1.0 eq) in DCM (25 ml), methanesulfonic acid (MSA, 0.29 mL, 4.4 mmol, 2.0 eq) was added under N2 gas. The clear solution was stirred overnight at room temperature. The next day, complete cleavage of the Boc group was confirmed by LC / MS. The reaction flask was cooled in an ice bath, and then chloroacetyl chloride (0.2 mL, 2.6 mmol, 1.15 eq.) was added, followed by the dropwise addition of triethylamine (1.6 mL, 11.2 mmol, 5.0 eq.). After 15 minutes, LC / MS confirmed that the reaction was complete. The reaction mixture was diluted with DCM (15 mL) and washed with water (20 ml) and brine (20 ml). The organic phase was dried over Na2SO4 and filtered. The organic phase was concentrated and purified by an ISCO MPLC system using a silica column (80 g). The column was eluted with a (0-50)% hexane-ethyl acetate gradient. The fractions were combined and concentrated using a rotary evaporator to obtain intermediate 4 (1.6 g, yield 87%) as a solid.

[0103] Step 5: To a solution of Intermediate 4 (480 mg, 0.65 mmol, 1 eq) in LC / MS grade acetonitrile (40 mL), dimethylamine (1.64 mL, 3.2 mmol, 5 eq, 2 M in THF) and DBU (2 eq.) were added at room temperature. The reaction mixture was stirred overnight at room temperature under N2 gas. The following day, LC / MS confirmed that the starting material had been consumed and completely converted to the product. The reaction mixture was concentrated, and the residue was suspended in DCM. The product was washed with saturated NaHCO3 aqueous solution, water, and brine. The organic phase was dried over Na2SO4 and filtered. The organic phase was concentrated and purified by an ISCO / MPLC system using a silica column (40 g). The column was eluted with a (0-100)% hexane-ethyl acetate and a (0-20)% DCM-MeOH gradient. The fractions were combined and concentrated using a rotary evaporator to obtain compound 8 (325 mg, 68% yield) as an oil. ESI MS (m / z): 737.72 (M+H) + .

[0104] Example 9: Synthesis of Compound 9 (2-(2-(cis-3,4-dihydroxypyrrolidine-1-yl)-N-(8-(heptadecan-9-yloxy)-8-oxooctyl)acetamide)ethyltetradecanoate) from Table 1 Compound 9 was prepared according to scheme 9 shown in Figure 9.

[0105] To a solution of intermediate 4 (520 mg, 0.71 mmol, 1 eq) from Example 8 in LC / MS grade acetonitrile (40 mL), cDHP.HCl (199 mg, 1.42 mmol, 2 eqs) and DBU (2 eqs) were added at room temperature. The reaction mixture was stirred overnight at 45 °C under N2 gas. The following day, LC / MS confirmed that the starting material had been consumed and completely converted to the product. The reaction mixture was concentrated, and the residue was suspended in DCM. The product was washed with saturated NaHCO3 aqueous solution, water, and brine. The organic phase was dried over Na2SO4 and filtered. The organic phase was concentrated and purified by an ISCO / MPLC system using a silica column (40 g). The column was eluted with a (0-100)% hexane-ethyl acetate and a (0-20)% DCM-MeOH gradient. The fractions were combined and concentrated using a rotary evaporator to obtain compound 9 (450 mg, 79% yield) as a viscous oil. ESI MS (m / z): 795.74 (M+H) + .

[0106] Example 10: Synthesis of Compound 10 (2-(N-(8-(heptadecane-9-yloxy)-8-oxooctyl)-1-methylpiperidine-4-carboxamide)ethyltetradecanoate) from Table 1 Compound 10 was prepared according to scheme 10 shown in Figure 10.

[0107] Step 4: Steps 1-3 of Scheme 10 were carried out in the same manner as described in Steps 1-3 of Scheme 8 above. To a solution of intermediate 3 (500 mg, 0.66 mmol, 1.0 eq) in DCM (20 ml), methanesulfonic acid (MSA, 86 μL, 1.32 mmol, 2.0 eq) was added under N2 gas. The clear solution was stirred overnight at room temperature. The next day, complete cleavage of the Boc group was confirmed by LC / MS. The reaction flask was cooled in an ice bath, and then saturated NaHCO3 aqueous solution was added. The reaction mixture was slowly warmed to room temperature. The organic phase was then separated. The aqueous phase was extracted with DCM (20 mL). The combined organic layers were dried over Na2SO4 and filtered. The organic phase was concentrated to obtain the crude amine intermediate, which was then used in the next step without further purification. This amine intermediate was dissolved in DCM (20 mL) and cooled to 0°C. N-methylpiperidinecarboxylic acid (142 mg, 0.99 mmol, 1.5 eq.), HATU (290 mg, 0.76 mmol, 1.15 eq.), and triethylamine (0.18 mL, 1.32 mmol, 2 eq.) were sequentially added to the above mixture. After 15 minutes, the cooler was removed and the reaction mixture was stirred at room temperature for 2 hours. Product formation was confirmed by LC / MS. The reaction mixture was diluted with DCM (20 mL) and washed with saturated NaHCO3 aqueous solution (25 mL), water (20 mL), and brine (20 mL). The organic phase was dried over Na2SO4 and filtered. The organic phase was concentrated and purified using an ISCO / MPLC system with a silica column (40 g). The column was eluted with a (0-100)% hexane-ethyl acetate and (0-20)% DCM-MeOH gradient. The fractions were combined and concentrated using a rotary evaporator to obtain compound 10 (300 mg, 59% yield) as an oily substance. ESI MS (m / z): 777.73 (M+H) + .

[0108] Example 11: Synthesis of Compound 11 (4-(N-(8-(heptadecane-9-yloxy)-8-oxooctyl)-1-methylpiperidine-4-carboxamide)butyltetradecanoate) from Table 1 Compound 11 was prepared according to scheme 11 shown in Figure 11.

[0109] Step 2: Step 1 of Scheme 11 was carried out according to the same procedure as described in Step 1 of Scheme 8 above. Intermediate 1 (3 g, 6.4 mmol, 1 eq.) and aminobutanol (1.7 g, 19.4 mmol, 3 eq.) were suspended in an acetonitrile / CPME mixture (40 mL, 1:1). K2CO3 (0.89 g, 6.4 mmol, 1 eq.) was added to the mixture. The reaction mixture was heated to 70°C and stirred for 5 hours. LC / MS confirmed that the reaction was complete. The heating bath was removed and the reaction mixture was cooled to room temperature. The solid was filtered and washed with acetonitrile. The reaction mixture was concentrated and the residue was suspended in DCM (50 mL). The organic layer was washed with saturated NaHCO3 aqueous solution (25 mL), water (25 mL), and brine (20 mL). The organic phase was dried over Na2SO4 and filtered. The organic phase was concentrated to obtain the mono-N-alkylation product in quantitative yield. This intermediate was dissolved in DCM (25 mL), and then Boc2O (1.6 g, 7.1 mmol, 1.1 eq.) and triethylamine (1.8 mL, 12.9 mmol, 2 eq.) were added. The reaction mixture was stirred overnight at room temperature. The following day, LC / MS indicated that the reaction was complete. The reaction mixture was diluted in DCM (30 mL) and then washed with saturated sodium bicarbonate solution (40 mL) and brine (40 mL). The organic phase was dried over sodium sulfate and filtered. The organic phase was concentrated, and the crude product was purified by ISCO / MPLC using a silica gel column (120 g). The column was eluted with a (0-60)% hexane-ethyl acetate gradient. The fractions were combined and concentrated under reduced pressure using a rotary evaporator to obtain intermediate 2 (2.0 g, yield 54%) as an oil.

[0110] Step 3: To a solution of intermediate 2 (2.0 g, 3.5 mmol, 1 eq.) in anhydrous DCM (25 ml), Et3N (0.97 mL, 7.0 mmol, 2 eq.) and myristoyl chloride (1.05 mL, 3.8 mmol, 1.1 eq.) were added at room temperature. After 1 hour, LC / MS confirmed that the reaction was complete. The reaction was stopped and diluted with DCM (20 mL). The organic matter was sequentially washed with saturated sodium bicarbonate solution (20 mL), water (20 mL), and brine solution (20 mL). The organic phase was dried over sodium sulfate and filtered. The organic phase was concentrated, and the crude product was purified by ISCO / MPLC using a silica gel column (80 g), and the column was eluted with a (0-50)% hexane-ethyl acetate gradient. The fractions were combined and concentrated under reduced pressure using a rotary evaporator to obtain intermediate 3 (2.4 g, yield 89%) as an oily substance.

[0111] Step 4: To a solution of intermediate 3 (500 mg, 0.64 mmol, 1.0 eq) in DCM (15 ml), methanesulfonic acid (MSA, 86 L, 1.32 mmol, 2.0 eq) was added under N2 gas. The clear solution was stirred overnight at room temperature. The next day, complete cleavage of the Boc group was confirmed by LC / MS. The reaction flask was cooled in an ice bath, and then N-methylpiperidinecarboxylic acid (183 mg, 1.28 mmol, 2 eq.), HATU (365 mg, 1.28 mmol, 1.5 eq.), and triethylamine (0.26 mL, 1.92 mmol, 3 eq.) were added sequentially. After 15 minutes, the ice bath was removed, and the reaction mixture was stirred for 30 minutes. Product formation was confirmed by LC / MS. The reaction mixture was diluted with DCM (20 mL) and washed with saturated NaHCO3 aqueous solution (20 mL), water (20 mL), and brine (20 mL). The organic phase was dried over Na2SO4 and filtered. The organic phase was concentrated and purified using an ISCO / MPLC system with a silica column (40 g). The column was eluted with a (0-100)% hexane-ethyl acetate and (0-20)% DCM-MeOH gradient. The fractions were combined and concentrated using a rotary evaporator to obtain compound 11 (356 mg, 69% yield) as an oil. ESI MS (m / z): 805.8 (M+H) + .

[0112] Example 12: Synthesis of Compound 12 (4-(2-(dimethylamino)-N-(8-(heptadecan-9-yloxy)-8-oxooctyl)acetamide)butyltetradecanoate) from Table 1 Compound 12 was prepared according to scheme 12 shown in Figure 12.

[0113] Step 4: Step 1 of Scheme 12 was carried out according to the same procedure as described in Step 1 of Scheme 8 above. Steps 2 and 3 of Scheme 12 were carried out according to the same procedure as described in Steps 2 and 3 of Scheme 11 above. Methanesulfonic acid (MSA, 0.3 mL, 4.6 mmol, 2.0 eq) was added to a solution of intermediate 3 (1.8 g, 2.3 mmol, 1.0 eq) in DCM (25 ml) under N2 gas. The clear solution was stirred overnight at room temperature. The next day, complete cleavage of the Boc group was confirmed by LC / MS. The reaction flask was cooled in an ice bath, and then chloroacetyl chloride (0.2 mL, 2.7 mmol, 1.1 eq.) was added, followed by the dropwise addition of triethylamine (1.6 mL, 11.5 mmol, 5.0 eq.). After 15 minutes, the reaction was confirmed to be complete by LC / MS. The reaction mixture was diluted with DCM (20 mL) and washed with water (20 mL) and brine (20 mL). The organic phase was dried over Na2SO4 and filtered. The organic phase was concentrated and purified using an ISCO MPLC system with a silica column (80 g). The column was eluted with a (0-50)% hexane-ethyl acetate gradient. The fractions were combined and concentrated using a rotary evaporator to obtain intermediate 4 (1.5 g, yield 88%) as an oily substance.

[0114] Step 5: To a solution of intermediate 4 (600 mg, 0.79 mmol, 1 eq) in LC / MS grade acetonitrile (40 mL), dimethylamine (1.9 mL, 3.9 mmol, 5 eq, 2 M in THF) and DBU (2 eq.) were added at room temperature. The reaction mixture was stirred overnight at room temperature under N2 gas. The following day, LC / MS confirmed that the starting materials had been consumed and completely converted to the product. The reaction mixture was concentrated, the residue was suspended in DCM, and washed with saturated NaHCO3 aqueous solution, water, and brine. The organic phase was dried over Na2SO4 and filtered. The organic phase was concentrated and purified by an ISCO / MPLC system using a silica column (40 g). The column was eluted with a (0-100)% hexane-ethyl acetate and a (0-20)% DCM-MeOH gradient. The fractions were combined and concentrated using a rotary evaporator to obtain compound 12 (436 mg, 72% yield) as an oil. ESI MS (m / z): 765.3 (M+H) + .

[0115] Example 13: Synthesis of Compound 13 (4-(2-(cis-3,4-dihydroxypyrrolidine-1-yl)-N-(8-(heptadecan-9-yloxy)-8-oxooctyl)acetamide)butyltetradecanoate) from Table 1 Compound 13 was prepared according to scheme 13 shown in Figure 13.

[0116] To a solution of intermediate 4 (580 mg, 0.76 mmol, 1 eq) from Example 12 in LC / MS grade acetonitrile (40 mL), cDHP.HCl (212 mg, 1.53 mmol, 2 eqs) and DBU (2 eqs) were added at room temperature. The reaction mixture was stirred overnight at 45 °C under N2 gas. The following day, LC / MS confirmed that the starting material had been consumed and completely converted to the product. The reaction mixture was concentrated, the residue was suspended in DCM, and washed with saturated NaHCO3 aqueous solution, water, and brine. The organic phase was dried over Na2SO4 and filtered. The organic phase was concentrated and purified by an ISCO / MPLC system using a silica column (40 g). The column was eluted with a (0-100)% hexane-ethyl acetate and a (0-20)% DCM-MeOH gradient. The fractions were combined and concentrated using a rotary evaporator to obtain compound 13 (476 mg, 75% yield) as a viscous oil. ESI MS (m / z): 823.79 (M+H) + .

[0117] Example 14: Synthesis of Compound 14 (3-(2-(dimethylamino)-N-(8-(heptadecane-9-yloxy)-8-oxooctyl)acetamide)propyltetradecanoate) from Table 1 Compound 14 was prepared according to scheme 14 shown in Figure 14.

[0118] Step 2: Step 1 of Scheme 14 was carried out according to the same procedure as described in Step 1 of Scheme 8 above. Intermediate 1 (2.8 g, 6.06 mmol, 1 eq.) and aminopropanol (1.4 g, 18.1 mmol, 3 eq.) were suspended in an acetonitrile / CPME mixture (40 mL, 1:1). K2CO3 (0.83 g, 12.9 mmol, 1 eq.) was added to the mixture. The reaction mixture was heated to 70°C and stirred for 5 hours. LC / MS confirmed that the reaction was complete. The heating bath was removed and the reaction mixture was cooled to room temperature. The solid was filtered and washed with acetonitrile. The reaction mixture was concentrated and the residue was suspended in DCM (40 mL). The organic layer was washed with saturated NaHCO3 aqueous solution (25 mL), water (25 mL), and brine (20 mL). The organic phase was dried over Na2SO4 and filtered. The organic phase was concentrated to obtain the mono-N-alkylation product in quantitative yield. This intermediate was dissolved in DCM (30 mL), and then Boc2O (1.6 g, 7.2 mmol, 1.2 eq.) and triethylamine (1.7 mL, 12.1 mmol, 2 eq.) were added. The reaction mixture was stirred overnight at room temperature. The following day, LC / MS indicated that the reaction was complete. The reaction mixture was diluted in DCM (30 mL) and then washed with saturated sodium bicarbonate solution (40 mL) and brine (40 mL). The organic phase was dried over sodium sulfate and filtered. The organic phase was concentrated, and the crude product was purified by ISCO / MPLC using a silica gel column (120 g). The column was eluted with a (0-100)% hexane-ethyl acetate gradient. The fractions were combined and concentrated under reduced pressure using a rotary evaporator to obtain intermediate 2 (2.0 g, yield 61%) as an oil.

[0119] Step 3: To a solution of intermediate 2 (2.0 g, 3.6 mmol, 1 eq.) in anhydrous DCM (25 ml), Et3N (0.97 mL, 7.2 mmol, 2 eq.) and myristoyl chloride (1.08 mL, 3.9 mmol, 1.1 eq.) were added at room temperature. After 2 hours, LC / MS confirmed that the reaction was complete. The reaction was stopped and diluted with DCM (20 mL). The organic matter was sequentially washed with saturated sodium bicarbonate solution (20 mL), water (20 mL), and brine solution (20 mL). The organic phase was dried over sodium sulfate and filtered. The organic phase was concentrated, and the crude product was purified by ISCO / MPLC using a silica gel column (80 g), and the column was eluted with a (0-50)% hexane-ethyl acetate gradient. The fractions were combined and concentrated under reduced pressure using a rotary evaporator to obtain intermediate 3 (1.8 g, yield 66.6%) as an oily substance.

[0120] Step 4: To a solution of intermediate 3 (450 mg, 0.58 mmol, 1 eq) in DCM (30 ml), methanesulfonic acid (MSA, 2.0 eq) was added under N2 gas. The clear solution was stirred overnight at room temperature. The next day, complete cleavage of the Boc group was confirmed by LC / MS. The reaction flask was cooled in an ice bath, and then saturated NaHCO3 aqueous solution was added. The reaction mixture was slowly warmed to room temperature. The organic phase was then separated. The aqueous phase was extracted with DCM (20 mL). The combined organic layers were dried over Na2SO4 and filtered. The organic phase was concentrated to obtain a crude amine intermediate, which was then used in the next step without further purification. This amine intermediate was dissolved in DCM (20 mL) and cooled to 0°C. N,N'-dimethylglycine HCl (163 mg, 1.17 mmol, 2 eq.), HATU (1.15 eq.), and triethylamine (2 eq.) were sequentially added to the mixture. After 15 minutes, the cooler was removed and the reaction mixture was stirred at room temperature for the required time. The reaction mixture was diluted with DCM (20 mL) and washed with saturated NaHCO3 aqueous solution (20 mL), water (20 mL), and brine (20 mL). The organic phase was dried over Na2SO4 and filtered. The organic phase was concentrated and purified using an ISCO / MPLC system with a silica column (40 g). The column was eluted with a (0-100)% hexane-ethyl acetate and a (0-20)% DCM-MeOH gradient. The fractions were combined and concentrated using a rotary evaporator to obtain compound 14 (275 mg, 63% yield) as an oil. ESI MS (m / z): 751.83 (M+H) + .

[0121] Example 15: Synthesis of Compound 15 (3-(N-(8-(heptadecan-9-yloxy)-8-oxooctyl)-2-(1-methylpiperidine-4-yl)acetamidopropyltetradecanoate) from Table 1 Compound 15 was prepared according to scheme 15 shown in Figure 15.

[0122] To a solution of intermediate 3 (450 mg, 0.58 mmol, 1 eq) from Example 14 in DCM (30 ml), methanesulfonic acid (MSA, 2.0 eq) was added under N2 gas. The clear solution was stirred overnight at room temperature. The following day, complete cleavage of the Boc group was confirmed by LC / MS. The reaction flask was cooled in an ice bath, and then saturated aqueous NaHCO3 solution was added. The reaction mixture was slowly warmed to room temperature. The organic phase was then separated. The aqueous phase was extracted with DCM (20 mL). The combined organic layers were dried over Na2SO4 and filtered. The organic phase was concentrated to obtain a crude amine intermediate, which was then used in the next step without further purification. This amine intermediate was dissolved in DCM (20 mL) and cooled to 0°C. N-methylpiperidine 4-acetic acid (227 mg, 1.17 mmol, 2 eq), HATU (1.15 eq.), and triethylamine (2 eq.) were sequentially added to the mixture. After 15 minutes, the cooler was removed and the reaction mixture was stirred at room temperature for the required time. The reaction mixture was diluted with DCM (20 mL) and washed with saturated NaHCO3 aqueous solution (20 mL), water (20 mL), and brine (20 mL). The organic phase was dried over Na2SO4 and filtered. The organic phase was concentrated and purified using an ISCO / MPLC system with a silica column (40 g). The column was eluted with a (0-100)% hexane-ethyl acetate and a (0-20)% DCM-MeOH gradient. The fractions were combined and concentrated using a rotary evaporator to obtain compound 15 (290 mg, yield 61%) as a viscous oil. ESI MS (m / z): 805.88 (M+H) + .

[0123] Example 16: Synthesis of Compound 16 (3-(N-(8-(heptadecane-9-yloxy)-8-oxooctyl)-1-methylpiperidine-4-carboxamide)propyltetradecanoate) from Table 1 Compound 16 was prepared according to scheme 16 shown in Figure 16.

[0124] To a solution of intermediate 3 (450 mg, 0.58 mmol, 1 eq) from Example 14 in DCM (30 ml), methanesulfonic acid (MSA, 2.0 eq) was added under N2 gas. The clear solution was stirred overnight at room temperature. The following day, complete cleavage of the Boc group was confirmed by LC / MS. The reaction flask was cooled in an ice bath, and then saturated aqueous NaHCO3 solution was added. The reaction mixture was slowly warmed to room temperature. The organic phase was then separated. The aqueous phase was extracted with DCM (20 mL). The combined organic layers were dried over Na2SO4 and filtered. The organic phase was concentrated to obtain a crude amine intermediate, which was then used in the next step without further purification. This amine intermediate was dissolved in DCM (20 mL) and cooled to 0°C. N-methylpiperidine 4-carboxylic acid (167 mg, 1.17, 2 eq.), HATU (1.15 eq.), and triethylamine (2 eq.) were sequentially added to the mixture. After 15 minutes, the cooler was removed and the reaction mixture was stirred at room temperature for the required time. The reaction mixture was diluted with DCM (20 mL) and washed with saturated NaHCO3 aqueous solution (20 mL), water (20 mL), and brine (20 mL). The organic phase was dried over Na2SO4 and filtered. The organic phase was concentrated and purified using an ISCO / MPLC system with a silica column (40 g). The column was eluted with a (0-100)% hexane-ethyl acetate and (0-20)% DCM-MeOH gradient. The fractions were combined and concentrated using a rotary evaporator to obtain compound 16 (292 mg, 63% yield) as an oil. ESI MS (m / z): 790.87 (M+H)+.

[0125] Example 17: Synthesis of Compound 17 (3-(2-(cis-3,4-dihydroxypyrrolidine-1-yl)-N-(8-(heptadecan-9-yloxy)-8-oxooctyl)acetamide)propyltetradecanoate) from Table 1 Compound 17 was prepared according to scheme 17 shown in Figure 17.

[0126] Step 4: Step 1 of Scheme 17 was carried out according to the same procedure as described in Step 1 of Scheme 8 above. Steps 2 and 3 of Scheme 17 were carried out according to the same procedure as described in Steps 2 and 3 of Scheme 14 above. Methanesulfonic acid (MSA, 80 mL, 1.17 mmol, 2.0 eq) was added to a solution of intermediate 3 (450 g, 0.58 mmol, 1.0 eq) in DCM (15 ml) under N2 gas. The clear solution was stirred overnight at room temperature. The next day, complete cleavage of the Boc group was confirmed by LC / MS. The reaction flask was cooled in an ice bath, and then chloroacetyl chloride (52 μL, 0.64 mmol, 1.1 eq.) was added, followed by the dropwise addition of triethylamine (0.4 mL, 2.9 mmol, 5.0 eq.). After 15 minutes, the ice bath was removed and the reaction mixture was cooled to room temperature. After stirring for 1 hour, the reaction was confirmed to be complete by LC / MS. The reaction mixture was diluted with DCM (20 mL) and washed with water (20 mL) and brine (20 mL). The organic phase was dried over Na2SO4 and filtered. The organic phase was concentrated and purified using an ISCO MPLC system with a silica column (40 g). The column was eluted with a (0-50)% hexane-ethyl acetate gradient. The fractions were combined and concentrated using a rotary evaporator to obtain intermediate 4 (425 mg, 97% yield) as a solid.

[0127] Step 5: Intermediate 4 (425 mg, 0.57 mmol, 1 eq) and cis-DHP.HCl (159 mg, 1.14 mmol, 2 eq.) were suspended in LC / MS grade acetonitrile (20 mL). DBU (144 μL, 1.14 mmol, 2 eq.) was added to the mixture. The reaction flask was heated to 45°C and stirred under N2 gas for 4 hours. LC / MS confirmed that the starting material had been consumed and the product had been formed. The heating bath was removed and the reaction mixture was stirred at room temperature overnight. The reaction mixture was concentrated, the residue was suspended in DCM (30 mL), and washed with saturated NaHCO3 aqueous solution (15 mL), water (15 mL), and brine (15 mL). The organic phase was dried over Na2SO4 and filtered. The organic phase was concentrated and purified by an ISCO / MPLC system using a silica column (40 g). The column was eluted using a (0-100)% hexane-ethyl acetate and (0-20)% DCM-MeOH gradient. The fractions were combined and concentrated using a rotary evaporator to obtain compound 17 (307 mg, 67% yield) as a viscous oil. ESI MS (m / z): 809.77 (M+H) + .

[0128] Example 18: Synthesis of Compound 18 (2-(2-(dimethylamino)-N-(8-(heptadecan-9-yloxy)-8-oxooctyl)acetamide)ethyl(9Z,12Z)-octadeca-9,12-dienoate) from Table 1 Compound 18 was prepared according to scheme 18 shown in Figure 18.

[0129] Step 3: Steps 1 and 2 of Scheme 18 were carried out in the same manner as described in Steps 1 and 2 of Scheme 8 above. To a mixture of Intermediate 2 (2.5 g, 4.6 mmol, 1 eq.) and linoleic acid (2.6 g, 9.2 mmol, 2 eq.) in anhydrous DCM (20 ml), EDC.HCl (1.7 g, 9.2 mmol, 1.5 eq.), Et3N (1.28 mL, 9.2 mmol, 2 eq.), and DMAP (220 mg, 1.8 mmol, 0.4 eq.) were sequentially added under nitrogen gas. The clear solution was stirred overnight at room temperature. The following day, LC / MS confirmed that the reaction was complete. The reaction was stopped and diluted with DCM (30 mL). The organic matter was sequentially washed with saturated sodium bicarbonate solution (30 mL) and brine solution (30 mL). The organic phase was dried over sodium sulfate and filtered. The organic phase was concentrated, and the crude product was purified by ISCO / MPLC using a silica gel column (80 g). The column was then eluted with a (0-50)% hexane-ethyl acetate gradient. The fractions were combined and concentrated under reduced pressure using a rotary evaporator to obtain intermediate 3 (3.15 g, yield 87%) as an oil.

[0130] Step 4: To a solution of intermediate 3 (1.2 g, 1.5 mmol, 1.0 eq) in DCM (20 ml), methanesulfonic acid (MSA, 0.2 mL, 3.0 mmol, 2.0 eq) was added under N2 gas. The clear solution was stirred overnight at room temperature. The next day, complete cleavage of the Boc group was confirmed by LC / MS. The reaction flask was cooled in an ice bath, and then chloroacetyl chloride (138 μL, 1.7 mmol, 1.15 eq.) was added, followed by the dropwise addition of triethylamine (1.0 mL, 7.5 mmol, 5.0 eq.). After 30 minutes, LC / MS confirmed that the reaction was complete. The reaction mixture was diluted with DCM (20 mL) and washed with water (20 ml) and brine (20 ml). The organic phase was dried over Na2SO4 and filtered. The organic phase was concentrated and purified by an ISCO MPLC system using a silica column (40 g). The column was eluted with a (0-40)% hexane-ethyl acetate gradient. The fractions were combined and concentrated using a rotary evaporator to obtain intermediate 4 (1.03 g, 88% yield) as a solid.

[0131] Step 5: To a solution of intermediate 4 (500 mg, 0.64 mmol, 1 eq) in LC / MS grade acetonitrile (40 mL), dimethylamine (1.6 mL, 3.2 mmol, 5 eq, 2 M in THF) and DBU (2 eq.) were added at room temperature. The reaction mixture was stirred overnight at room temperature under N2 gas. The following day, LC / MS confirmed that the starting materials had been consumed and completely converted to the product. The reaction mixture was concentrated, the residue was suspended in DCM, and washed with saturated NaHCO3 aqueous solution, water, and brine. The organic phase was dried over Na2SO4 and filtered. The organic phase was concentrated and purified by an ISCO / MPLC system using a silica column (40 g). The column was eluted with a (0-100)% hexane-ethyl acetate and a (0-20)% DCM-MeOH gradient. The fractions were combined and concentrated using a rotary evaporator to obtain compound 18 (335 mg, 66% yield) as an oil. ESI MS (m / z): 789.83 (M+H) + .

[0132] Example 19: Synthesis of Compound 19 (2-(2-(cis-3,4-dihydroxypyrrolidine-1-yl)-N-(8-(heptadecan-9-yloxy)-8-oxooctyl)acetamide)ethyl(9Z,12Z)-octadeca-9,12-dienoate) from Table 1 Compound 19 was prepared according to scheme 19 shown in Figure 19.

[0133] To a solution of intermediate 4 (500 mg, 0.64 mmol, 1 eq) from Example 18 in LC / MS grade acetonitrile (40 mL), cDHP.HCl (177 mg, 1.28 mmol, 2 eqs) and DBU (2 eqs) were added at room temperature. The reaction mixture was stirred overnight at 45 °C under N2 gas. The following day, LC / MS confirmed that the starting material had been consumed and completely converted to the product. The reaction mixture was concentrated, the residue was suspended in DCM, and washed with saturated NaHCO3 aqueous solution, water, and brine. The organic phase was dried over Na2SO4 and filtered. The organic phase was concentrated and purified by an ISCO / MPLC system using a silica column (40 g). The column was eluted with a (0-100)% hexane-ethyl acetate and a (0-20)% DCM-MeOH gradient. The fractions were combined and concentrated using a rotary evaporator to obtain compound 19 (400 mg, 74% yield) as a viscous oil. ESI MS (m / z): 847.89 (M+H) + .

[0134] Example 20: Synthesis of Compound 20 (2-(N-(8-(heptadecan-9-yloxy)-8-oxooctyl)-2-(1-methylpiperidine-4-yl)acetamido)ethyl(9Z,12Z)-octadeca-9,12-dienoate) from Table 1 Compound 20 was prepared according to scheme 20 shown in Figure 20.

[0135] Step 4: Steps 1 and 2 of Scheme 20 were carried out in the same manner as described in Steps 1 and 2 of Scheme 8. Step 3 of Scheme 20 was carried out in the same manner as described in Step 3 of Example 18. Methanesulfonic acid (MSA, 0.32 mL, 4.7 mmol, 2.0 eq) was added to a solution of intermediate 3 (1.9 g, 2.3 mmol, 1.0 eq) in DCM (20 ml) under N2 gas. The clear solution was stirred overnight at room temperature. The next day, complete cleavage of the Boc group was confirmed by LC / MS. The obtained amine intermediate was dissolved in DCM (20 mL) and cooled to 0°C. N-methylpiperidine 4-acetic acid (1.5 eq.), HATU (1.15 eq.), and triethylamine (2 eq.) were added sequentially to the mixture. After 15 minutes, the cooler was removed and the reaction mixture was stirred at room temperature for the required time. The reaction mixture was diluted with DCM (20 mL) and washed with saturated NaHCO3 aqueous solution (20 mL), water (20 mL), and brine (20 mL). The organic phase was dried over Na2SO4 and filtered. The organic phase was concentrated and purified using an ISCO / MPLC system with a silica column (40 g). The column was eluted with a (0-100)% hexane-ethyl acetate and (0-20)% DCM-MeOH gradient. The fractions were combined and concentrated using a rotary evaporator to obtain compound 20 (503 mg, 75% yield) as an oil. ESI MS (m / z): 843.4 (M+H) + .

[0136] Example 21: Synthesis of Compound 21(2-(N-(8-(heptadecan-9-yloxy)-8-oxooctyl)-1-methylpiperidine-4-carboxamide)ethyl(9Z,12Z)-octadeca-9,12-dienoate) from Table 1 Compound 21 was prepared according to scheme 21 shown in Figure 21.

[0137] To a solution of intermediate 3 (1.9 g, 2.3 mmol, 1.0 eq) from Example 20 in DCM (20 ml), methanesulfonic acid (MSA, 0.32 mL, 4.7 mmol, 2.0 eq) was added under N2 gas. The clear solution was stirred overnight at room temperature. The following day, complete cleavage of the Boc group was confirmed by LC / MS. The obtained amine intermediate was dissolved in DCM (20 mL) and cooled to 0°C. N-methylpiperidine 4-carboxylic acid (1.5 eq.), HATU (1.15 eq.), and triethylamine (2 eq.) were sequentially added to the mixture. After 15 minutes, the cooler was removed and the reaction mixture was stirred at room temperature for the required time. The reaction mixture was diluted with DCM (20 mL) and washed with saturated NaHCO3 aqueous solution (20 mL), water (20 mL), and brine (20 mL). The organic phase was dried over Na2SO4 and filtered. The organic phase was concentrated and purified using an ISCO / MPLC system with a silica column (40 g). The column was eluted with a (0-100)% hexane-ethyl acetate and a (0-20)% DCM-MeOH gradient. The fractions were combined and concentrated using a rotary evaporator to obtain compound 21 (530 mg, 82% yield) as a viscous oil. ESI MS (m / z): 829.4 (M+H) + .

[0138] Example 22: Synthesis of Compound 22(2-(2-(dimethylamino)-N-(6-oxo-6-(tridecane-7-yloxy)hexyl)acetamido)ethyl(9Z,12Z)-octadeca-9,12-dienoate) from Table 1 Compound 22 was prepared according to scheme 22 shown in Figure 22.

[0139] Step 1: DMAP (300 mg, 2.9 mmol, 0.1 eq.) and EDC·HCl (6.8 g, 35.9 mmol, 1.2 eq.) were added to a stirred solution of tridecane-7-ol (6 g, 29.9 mmol, 1 eq.) and 6-bromohexanoic acid (7 g, 35.9 mmol, 1.2 eq.) in DCM (70 mL). The clear reaction solution was stirred overnight at room temperature under nitrogen gas. The reaction mixture was diluted with DCM (50 mL) and then washed with saturated sodium bicarbonate solution (40 mL), water (40 mL), and brine (40 mL). The organic phase was dried over sodium sulfate and filtered. The organic phase was concentrated to obtain intermediate 1 (7.2 g, yield 66%).

[0140] Step 2: Intermediate 1 (2.3 g, 6.1 mmol, 1 eq.) and aminoethanol (2.6 g, 42.7 mmol, 7 eq.) were suspended in an acetonitrile / CPME mixture (60 mL, 1:1). K2CO3 (0.84 g, 12.9 mmol, 1 eq.) was added to the mixture. The reaction mixture was heated to 70°C and stirred for 5 hours. LC / MS confirmed that the reaction was complete. The heating bath was removed and the reaction mixture was cooled to room temperature. The solid was filtered and washed with acetonitrile. The filtrate was concentrated and the residue was suspended in DCM (60 mL). The organic layer was washed with saturated NaHCO3 aqueous solution (30 mL), water (30 mL), and brine (30 mL). The organic phase was dried over Na2SO4 and filtered. The organic phase was concentrated to obtain the mono-N-alkylation product in quantitative yield. This intermediate was dissolved in DCM (50 mL), and then Boc2O (1.4 g, 6.7 mmol, 1.1 eq.) and triethylamine (1.7 mL, 12.2 mmol, 2 eq.) were added to the mixture. The mixture was stirred overnight at room temperature. The next day, LC / MS showed that the reaction was complete. The reaction mixture was diluted in DCM (30 mL) and then washed with saturated sodium bicarbonate solution (40 mL) and brine (40 mL). The organic phase was dried over sodium sulfate and filtered. The organic phase was concentrated, and the crude product was purified by ISCO / MPLC using a silica gel column (80 g). The column was eluted with a (0-100)% hexane-ethyl acetate gradient. The fractions were combined and concentrated under reduced pressure using a rotary evaporator to obtain intermediate 2 (1.3 g, yield 62%) as an oil.

[0141] Step 3: EDC.HCl (0.81 g, 4.2 mmol, 1.5 eq.), Et3N (0.79 mL, 5.6 mmol, 2 eq.), and DMAP (138 mg, 1.1 mmol, 0.4 eq.) were sequentially added under nitrogen gas to a mixture of intermediate 2 (1.3 g, 2.8 mmol, 1 eq.) and linoleic acid (1.2 g, 4.2 mmol, 1.5 eq.) in anhydrous DCM (20 mL). The clear solution was stirred overnight at room temperature. The next day, LC / MS confirmed that the reaction was complete. The reaction was stopped and diluted with DCM (30 mL). The organic matter was sequentially washed with saturated sodium bicarbonate solution (30 mL) and brine solution (30 mL). The organic phase was dried over sodium sulfate and filtered. The organic phase was concentrated, and the crude product was purified by ISCO / MPLC using a silica gel column (80 g). The column was then eluted with a (0-50)% hexane-ethyl acetate gradient. The fractions were combined and concentrated under reduced pressure using a rotary evaporator to obtain intermediate 3 (1.5 g, 75% yield) as an oil.

[0142] Step 4: Methanesulfonic acid (MSA, 72 μL, 1.1 mmol, 2.0 eq) was added to a solution of intermediate 3 (400 mg, 0.55 mmol, 1.0 eq) in DCM (20 ml) under N2 gas. The clear solution was stirred overnight at room temperature. The next day, complete cleavage of the Boc group was confirmed by LC / MS. N,N'-dimethylglycine (72 mg, 0.72 mmol, 1.3 eq), HATU (316 mg, 0.83 mmol, 1.4 eq), and diisopropylethylamine (0.5 mL, 2.7 mmol, 5 eq) were added sequentially to the above reaction mixture. The resulting solution was stirred at ambient temperature under N2 gas for 3 hours. LC / MS showed that the reaction was a complete transformation. The reaction mixture was diluted with DCM (20 mL) and washed with saturated NaHCO3 aqueous solution (10 mL), water (10 mL), and brine (10 mL). The organic phase was dried over Na2SO4 and filtered. The organic phase was concentrated and purified using an ISCO / MPLC system with a silica column (24 g). The column was eluted with a (0-100)% hexane-ethyl acetate and a (0-20)% DCM-MeOH gradient. The fractions were combined and concentrated using a rotary evaporator to obtain compound 22 (145 mg, 37% yield) as an oil. ESI MS (m / z): 705.66 (M+H) + .

[0143] Example 23: Synthesis of Compound 23 (2-(4-(dimethylamino)-N-(6-oxo-6-(tridecane-7-yloxy)hexyl)butanamide)ethyl(9Z,12Z)-octadeca-9,12-dienoate) from Table 1 Methanesulfonic acid (MSA, 72 μL, 1.1 mmol, 2.0 eq) was added to a solution of intermediate 3 of Example 22 (400 mg, 0.55 mmol, 1.0 eq) in DCM (20 ml) under N2 gas. The clear solution was stirred overnight at room temperature. The following day, complete cleavage of the Boc group was confirmed by LC / MS. N,N'-dimethylbutanoic acid (94 mg, 0.72 mmol, 1.3 eq), HATU (316 mg, 0.83 mmol, 1.4 eq), and diisopropylethylamine (0.5 mL, 2.7 mmol, 5 eq) were added sequentially to the above reaction mixture. The resulting solution was stirred at ambient temperature under N2 gas for 3 hours. LC / MS showed that the reaction was a complete transformation. The reaction mixture was diluted with DCM (20 mL) and washed with saturated NaHCO3 aqueous solution (10 mL), water (10 mL), and brine (10 mL). The organic phase was dried over Na2SO4 and filtered. The organic phase was concentrated and purified using an ISCO / MPLC system with a silica column (24 g). The column was eluted with a (0-100)% hexane-ethyl acetate and (0-20)% DCM-MeOH gradient. The fractions were combined and concentrated using a rotary evaporator to obtain compound 23 (160 mg, 37% yield) as an oil. ESI MS (m / z): 733.71 (M+H) + .

[0144] Example 24: Synthesis of Compound 24(2-(2-((2-(dimethylamino)ethyl)thio)-N-(6-oxo-6-(tridecane-7-yloxy)hexyl)acetamido)ethyl(9Z,12Z)-octadeca-9,12-dienoate) from Table 1 Methanesulfonic acid (MSA, 72 μL, 1.1 mmol, 2.0 eq) was added to a solution of intermediate 3 of Example 22 (400 mg, 0.55 mmol, 1.0 eq) in DCM (20 ml) under N2 gas. The clear solution was stirred overnight at room temperature. The following day, complete cleavage of the Boc group was confirmed by LC / MS. N,N'-dimethylethylthioacetic acid (117 mg, 2.7 mmol, 5 eq), HATU (316 mg, 0.83 mmol, 1.4 eq), and diisopropylethylamine (0.5 mL, 1.0 mmol) were added sequentially to the above reaction mixture. The resulting solution was stirred at ambient temperature under N2 gas for 3 hours. LC / MS showed that the reaction was a complete transformation. The reaction mixture was diluted with DCM (20 mL) and washed with saturated NaHCO3 aqueous solution (10 mL), water (10 mL), and brine (10 mL). The organic phase was dried over Na2SO4 and filtered. The organic phase was concentrated and purified using an ISCO / MPLC system with a silica column (24 g). The column was eluted with a (0-100)% hexane-ethyl acetate and (0-20)% DCM-MeOH gradient. The fractions were combined and concentrated using a rotary evaporator to obtain compound 24 (170 mg, 37% yield) as an oil. ESI MS (m / z): 765.98 (M+H) + .

[0145] Example 25: Synthesis of Compound 25 (Tridecane-7-yl6-(2-(dimethylamino)-N-(6-oxo-6-(undecyloxy)hexyl)acetamide)hexanoate) from Table 1 Compound 25 was prepared according to scheme 23 shown in Figure 23.

[0146] Step 1: DMAP (300 mg, 2.9 mmol, 0.1 eq.) and EDC·HCl (6.8 g, 35.9 mmol, 1.2 eq.) were added to a stirred solution of tridecane-7-ol (6 g, 29.9 mmol, 1 eq.) and 6-bromohexanoic acid (7 g, 35.9 mmol, 1.2 eq.) in DCM (70 mL). The clear reaction solution was stirred overnight at room temperature under nitrogen gas. The reaction mixture was diluted with DCM (50 mL) and then washed with saturated sodium bicarbonate solution (40 mL), water (40 mL), and brine (40 mL). The organic phase was dried over sodium sulfate and filtered. The organic phase was concentrated to obtain intermediate 1 (7.2 g, yield 66%).

[0147] Step 2: To a solution of undecane-1-ol (5 g, 29.0 mmol, 1 eq.) and 6-N-Boc-aminohexanoic acid (8 g, 34.8 mmol, 1.2 eq.) in anhydrous DCM (70 ml), EDC·HCl (8.3 g, 43.5 mmol, 1.5 eq.), triethylamine (5.8 mL, 58 mmol), and DMAP (700 mg, 2.9 mmol, 0.2 eq.) were added. The clear reaction solution was stirred overnight at room temperature under N2 gas. The next day, the completion of the reaction was confirmed by LC / MS. The reaction mixture was diluted with DCM (50 mL) and then washed with saturated sodium bicarbonate solution (60 mL) and brine (60 mL). The organic phase was dried over sodium sulfate, filtered, and the solvent was evaporated using a rotary evaporator to obtain the crude product. The organic phase was dried over Na2SO4 and filtered. The organic phase was concentrated, and the crude product was purified by ISCO MPLC using a silica gel column (120 g). The column was then eluted with a (0-100)% hexane-ethyl acetate gradient. The fractions were combined and concentrated to obtain intermediate 2 (9.3 g, 79% yield) as an oily substance.

[0148] Step 3: Intermediate 2 (6 g, 15.5 mmol, 1 eq) was dissolved in DCM (60 mL), and methanesulfonic acid (2.0 mL, 31.1 mmol, 2 eq) was added to the solution. The clear solution was stirred overnight at room temperature. The following day, LC / MS confirmed the complete conversion of the starting material to the product. The reaction mixture was diluted with DCM (40 mL) and washed with saturated sodium bicarbonate solution (40 mL). The organic phase was dried over Na2SO4 and filtered. The organic phase was concentrated and dried to obtain the free amine intermediate in quantitative yield. This material was used in the next step without further purification. Solutions of intermediate 1 (1.5 g, 3.9 mmol, 1 eq.) and the deprotected product of intermediate 2 (2.2 g, 7.9 mmol, 2 eq.) in an acetonitrile / cyclopropyl methyl ether mixture (60 mL, 1:1) were treated with potassium carbonate (1.0 g, 7.9 mmol, 2 eq.) under N2 gas. The reaction flask was heated overnight at 70°C. LC / MS showed the formation of the desired peak corresponding to the monoalkylation product. The reaction mixture was cooled to room temperature, filtered through a Celite pad, and washed with DCM (40 mL). The organic phase was concentrated and purified using an ISCO MPLC system with a silica column (80 g). The column was eluted with a (0-100)% hexane / ÃA gradient. The fractions were combined and concentrated under reduced pressure using a rotary evaporator to obtain intermediate 3 (450 mg, 20% yield) as a solid. ESI MS (m / z): 582.63 (M+H) + .

[0149] Step 4: Diisopropylethylamine (184 μL, 1.0 mmol) was added to a mixture of intermediate 3 (150 mg, 0.25 mmol, 1 eq) and N,N'-dimethylglycine (31 mg, 0.30 mmol, 1.2 eq) in DCM (5 ml), followed by the addition of HATU (137 mg, 0.37 mmol, 1.4 eq). The resulting solution was stirred overnight at ambient temperature under N2 gas. The next day, LC-MS showed that the reaction was a complete transformation. The reaction mixture was diluted with DCM (20 mL) and washed with saturated NaHCO3 aqueous solution (10 mL), water (10 mL), and brine (10 mL). The organic phase was dried over Na2SO4 and filtered. The organic phase was concentrated and purified by an ISCO / MPLC system using a silica column (12 g). The column was eluted with a (0-100)% hexane-ethyl acetate and (0-20)% DCM-MeOH gradient. The fractions were combined and concentrated using a rotary evaporator to obtain compound 25 (96 mg, 56% yield) as an oil. ESI MS (m / z): 667.66 (M+H) + .

[0150] Example 26: Synthesis of Compound 26 (Tridecane-7-yl6-(N-(6-oxo-6-(undecyloxy)hexyl)-2-(pyrrolidine-1-yl)acetamide)hexanoate) from Table 1 Diisopropylethylamine (184 μL, 1.0 mmol) was added to a mixture of intermediate 3 (150 mg, 0.25 mmol, 1 eq) from Example 25 and pyrrolidineacetic acid (51 mg, 0.30 mmol, 1.2 eq) in DCM (5 ml), followed by HATU (137 mg, 0.37 mmol, 1.4 eq). The resulting solution was stirred overnight at ambient temperature under N2 gas. The next day, LC-MS showed that the reaction was a complete transformation. The reaction mixture was diluted with DCM (20 mL) and washed with saturated NaHCO3 aqueous solution (10 mL), water (10 mL), and brine (10 mL). The organic phase was dried over Na2SO4 and filtered. The organic phase was concentrated and purified by an ISCO / MPLC system using a silica column (12 g). The column was eluted with a (0-100)% hexane-ethyl acetate and a (0-20)% DCM-MeOH gradient. The fractions were combined and concentrated using a rotary evaporator to obtain compound 26 (146 mg, 82% yield) as an oil. ESI MS (m / z): 693.67 (M+H) + .

[0151] Example 27: Synthesis of Compound 27 (Tridecane-7-yl6-(2-((2-(dimethylamino)ethyl)thio)-N-(6-oxo-6-(undecyloxy)hexyl)acetamide)hexanoate) from Table 1 Diisopropylethylamine (184 μL, 1.0 mmol) was added to a mixture of intermediate 3 from Example 25 (150 mg, 0.27 mmol, 1 eq) and N,N'-dimethylethylthioacetic acid (50 mg, 0.30 mmol, 1.2 eq) in DCM (5 ml), followed by HATU (137 mg, 0.37 mmol, 1.4 eq). The resulting solution was stirred overnight at ambient temperature under N2 gas. The next day, LC-MS showed that the reaction was a complete transformation. The reaction mixture was diluted with DCM (20 mL) and washed with saturated NaHCO3 aqueous solution (10 mL), water (10 mL), and brine (10 mL). The organic phase was dried over Na2SO4 and filtered. The organic phase was concentrated and purified by an ISCO / MPLC system using a silica column (12 g). The column was eluted using a (0-100)% hexane-ethyl acetate and (0-20)% DCM-MeOH gradient. The fractions were combined and concentrated using a rotary evaporator to obtain compound 27 (115 mg, 61% yield) as an oil. ESI MS (m / z): 727.6 (M+H) + .

[0152] Example 28: Synthesis of Compound 28 (Tridecane-7-yl6-(2-(dimethylamino)-N-(4-oxo-4-(undecyloxy)butyl)acetamide)hexanoate) from Table 1 Compound 28 was prepared according to scheme 24 shown in Figure 24.

[0153] Step 1: To a stirred solution of tridecane-7-ol (6 g, 29.9 mmol, 1 eq.) and 6-bromohexanoic acid (7 g, 35.9 mmol, 1.2 eq.) in DCM (70 mL), DMAP (300 mg, 2.9 mmol, 0.1 eq.) and EDC·HCl (6.8 g, 35.9 mmol, 1.2 eq.) were added. The clear reaction solution was stirred overnight at room temperature under nitrogen gas. The reaction mixture was diluted with DCM (50 mL) and then washed with saturated sodium bicarbonate solution (40 mL), water (40 mL), and brine (40 mL). The organic phase was dried over sodium sulfate and filtered. The organic phase was concentrated to obtain intermediate 1 (7.2 g, yield 66%).

[0154] Step 2: To a solution of undecane-1-ol (3 g, 17.4 mmol, 1 eq.) and 6-N-Boc aminobutanoic acid (4.2 g, 20.8 mmol, 1.2 eq.) in anhydrous DCM (50 ml), EDC·HCl (5 g, 26.4 mmol, 1.5 eq.), triethylamine (4.9 mL, 34.8 mmol), and DMAP (424 mg, 3.4 mmol, 0.2 eq.) were added. The clear reaction solution was stirred overnight at room temperature under N2 gas. The next day, the completion of the reaction was confirmed by LC / MS. The reaction mixture was diluted with DCM (30 mL) and then washed with saturated sodium bicarbonate solution (40 mL) and brine (40 mL). The organic phase was dried over sodium sulfate, filtered, and the solvent was evaporated using a rotary evaporator to obtain the crude product. The organic phase was dried over Na2SO4 and filtered. The crude product was concentrated and purified by ISCO MPLC using a silica gel column (120 g), and the column was eluted with a (0-100)% hexane-ethyl acetate gradient. The fractions were combined and concentrated to obtain intermediate 2 (5.5 g, yield 88%) as an oil.

[0155] Step 3: Intermediate 2 (3.7 g, 10.3 mmol) was dissolved in DCM (40 mL), and methanesulfonic acid (1.3 mL, 20.6 mmol, 2 eq) was added to the solution. The clear solution was stirred overnight at room temperature. The following day, LC / MS confirmed the complete conversion of the starting material to the product. The reaction mixture was diluted with DCM (25 mL) and washed with saturated sodium bicarbonate solution (25 mL). The organic phase was dried over Na2SO4 and filtered. The organic phase was concentrated and dried to obtain the free amine intermediate in quantitative yield. This material was used in the next step without further purification. Solutions of intermediate 1 (1.0 g, 2.6 mmol, 1 eq.) and the deprotected product of intermediate 2 (1.3 g, 5.2 mmol, 2 eq.) in an acetonitrile / cyclopropyl methyl ether mixture (50 mL, 1:1) were treated with potassium carbonate (730 mg, 5.3 mmol, 2 eq.) under N2 gas. The reaction flask was heated overnight at 70°C. LC / MS showed the formation of the desired peak corresponding to the monoalkylation product. The reaction mixture was cooled to room temperature, filtered through a Celite pad, and washed with DCM (20 mL). The organic phase was concentrated and purified using an ISCO MPLC system with a silica column (80 g). The column was eluted with a (0-100)% hexane / Ã gradient. The fraction was concentrated under reduced pressure using a rotary evaporator to obtain intermediate 3 (300 mg, 21% yield) as a solid. ESI MS (m / z): 554.56 (M+H) + .

[0156] Step 4: To a mixture of intermediate 3 (150 mg, 0.27 mmol, 1 eq) and N,N'-dimethylglycine (33 mg, 0.32 mmol, 1.2 eq) in DCM (5 ml), triethylamine (152 μL, 1.0 mmol) was added, followed by HATU (144 mg, 0.37 mmol, 1.4 eq). The resulting solution was stirred overnight at ambient temperature under N2 gas. The next day, LC-MS showed that the reaction was a complete transformation. The reaction mixture was diluted with DCM (20 mL) and washed with saturated NaHCO3 aqueous solution (20 mL), water (20 mL), and brine (20 mL). The organic phase was dried over Na2SO4 and filtered. The organic phase was concentrated and purified by an ISCO / MPLC system using a silica column (12 g). The column was eluted with a (0-100)% hexane-ethyl acetate and (0-20)% DCM-MeOH gradient. The fractions were combined and concentrated using a rotary evaporator to obtain compound 28 (96 mg, 55% yield) as an oil. ESI MS (m / z): 639.63 (M+H) + .

[0157] Example 29: Synthesis of Compound 29 (Tridecane-7-yl6-(2-((2-(dimethylamino)ethyl)thio)-N-(4-oxo-4-(undecyloxy)butyl)acetamide)hexanoate) from Table 1 To a mixture of intermediate 3 from Example 28 (150 mg, 0.27 mmol, 1 eq) and N,N'-dimethylethylthioacetic acid (52 mg, 0.32 mmol, 1.2 eq) in DCM (5 ml), triethylamine (152 μL, 1.0 mmol) was added, followed by HATU (144 mg, 0.37 mmol, 1.4 eq). The resulting solution was stirred overnight at ambient temperature under N2 gas. The next day, LC-MS showed that the reaction was a complete transformation. The reaction mixture was diluted with DCM (20 mL) and washed with saturated NaHCO3 aqueous solution (20 mL), water (20 mL), and brine (20 mL). The organic phase was dried over Na2SO4 and filtered. The organic phase was concentrated and purified by an ISCO / MPLC system using a silica column (12 g). The column was eluted with a (0-100)% hexane-ethyl acetate and (0-20)% DCM-MeOH gradient. The fractions were combined and concentrated using a rotary evaporator to obtain compound 29 (147 mg, 77% yield) as an oily substance. ESI MS (m / z): 699.63 (M+H) + .

[0158] Example 30: Synthesis of Compound 30 (Tetradecan-5-yl 6-(2-(dimethylamino)-N-(6-oxo-6-(undecyloxy)hexyl)acetamide)hexanoate) from Table 1 Compound 30 was prepared according to scheme 25 shown in Figure 25.

[0159] Step 1: Triethylamine (3.9 mL, 27 mmol, 2 eq.) was added to a stirred solution of tetradecane-5-ol (3.0 g, 13.9 mmol, 1 eq.) in anhydrous DCM (40 mL). After stirring for 10 minutes, 6-bromohexanoyl chloride (3.2 g, 35.9 mmol, 1.2 eq.) was slowly added to the mixture. The clear reaction solution was stirred at room temperature under nitrogen gas for 5 hours. The reaction mixture was diluted with DCM (50 mL) and then washed with water (40 mL) and brine (40 mL). The organic phase was dried over sodium sulfate and filtered. The organic phase was concentrated, and the crude product was purified by ISCO MPLC using a silica gel column (120 g), and the column was eluted with a (0-30)% hexane-ethyl acetate gradient. The organic phase was concentrated to obtain intermediate 1 (1.4 g, yield 66%).

[0160] Step 2: To a solution of undecane-1-ol (5 g, 29.0 mmol, 1 eq.) and 6-N-Boc-aminohexanoic acid (8 g, 34.8 mmol, 1.2 eq.) in anhydrous DCM (70 ml), EDC·HCl (8.3 g, 43.5 mmol, 1.5 eq.), triethylamine (5.8 mL, 58 mmol), and DMAP (700 mg, 2.9 mmol, 0.2 eq.) were added. The clear reaction solution was stirred overnight at room temperature under N2 gas. The next day, the completion of the reaction was confirmed by LC / MS. The reaction mixture was diluted with DCM (50 mL) and then washed with saturated sodium bicarbonate solution (60 mL) and brine (60 mL). The organic phase was dried over sodium sulfate, filtered, and the solvent was evaporated using a rotary evaporator to obtain the crude product. The organic phase was dried over Na2SO4 and filtered. The organic phase was concentrated, and the crude product was purified by ISCO MPLC using a silica gel column (120 g). The column was then eluted with a (0-100)% hexane-ethyl acetate gradient. The fractions were combined and concentrated to obtain intermediate 2 (9.3 g, 79% yield) as an oily substance.

[0161] Step 3: Intermediate 2 (6 g, 15.5 mmol, 1 eq) was dissolved in DCM (60 mL), and methanesulfonic acid (2.0 mL, 31.1 mmol, 2 eq) was added. The clear solution was stirred overnight at room temperature. The following day, LC / MS confirmed the complete conversion of the starting material to the product. The reaction mixture was diluted with DCM (40 mL) and washed with saturated sodium bicarbonate solution (40 mL). The organic phase was dried over Na2SO4 and filtered. The organic phase was concentrated and dried to obtain the free amine intermediate in quantitative yield. This material was used in the next step without further purification. Solutions of intermediate 1 (0.8 g, 2.0 mmol, 1 eq.) and the deprotected product of intermediate 2 (1.1 g, 4.0 mmol, 2 eq.) in an acetonitrile / cyclopropyl methyl ether mixture (40 mL, 1:1) were treated with potassium carbonate (280 mg, 2.0 mmol, 2 eq.) under N2 gas. The reaction flask was heated at 70°C for 3 hours. LC / MS showed the formation of the desired peak corresponding to the monoalkylation product. The reaction mixture was cooled to room temperature, filtered through a Celite pad, and washed with DCM (20 mL). The crude product was concentrated and purified using an ISCO MPLC system with a silica column (80 g). The column was eluted with a (0-100)% hexane / Â gradient. The fractions were combined and concentrated under reduced pressure using a rotary evaporator to obtain intermediate 3 (130 mg, 10% yield) as a solid.

[0162] Step 4: Compound 30: Diisopropylethylamine (77 μL, 0.43 mmol) was added to a mixture of intermediate 3 (130 mg, 0.21 mmol, 1 eq) and N,N'-dimethylglycine (26 mg, 0.30 mmol, 1.2 eq) in DCM (5 ml), followed by the addition of HATU (116 mg, 0.30 mmol, 1.4 eq). The resulting solution was stirred overnight at ambient temperature under N2 gas. The next day, LC-MS showed that the reaction was a complete transformation. The reaction mixture was diluted with DCM (20 mL) and washed with saturated NaHCO3 aqueous solution (10 mL), water (10 mL), and brine (10 mL). The organic phase was dried over Na2SO4 and filtered. The organic phase was concentrated and purified by an ISCO / MPLC system using a silica column (12 g). The column was eluted using a (0-100)% hexane-ethyl acetate and (0-20)% DCM-MeOH gradient. The fractions were combined and concentrated using a rotary evaporator to obtain compound 30 (74 mg, 50% yield) as an oil. ESI MS (m / z): 682.69(M+H) + .

[0163] Example 31: In vitro activity of LNP formulation The siRNA sequences used in this study were as follows: ●Sense chain sequence number 1 (5'->3'): TIFF0007954317000027.tif659●Antisense chain sequence number 2(5'->3'): In the sequence TIFF0007954317000028.tif659, A, G, C, and U refer to ribo-A, ribo-G, ribo-C, and ribo-U, respectively; lowercase a, u, g, c, and t refer to 2'-deoxy-A, 2'-deoxy-U, 2'-deoxy-G, 2'-deoxy-C, and deoxythymidine (dT=T=t), respectively; underscores refer to 2'-OMe substitutions; and lowercase f refers to 2'-deoxy-2'-fluoro substitutions. siRNA can knock down the GSTp gene, which is disclosed in PCT Publication WO2016 / 106400, the entire document of which is expressly incorporated herein by reference.

[0164] The LNP formulation was prepared with the following composition: (Test compound / Cholesterol / DSPC / DMG-PEG) = 50 / 38 / 10 / 2 (mol%)

[0165] The test compounds were selected from the group consisting of compound numbers 1 to 21, R1, and R2. R1 was a commercially available product. R2 was prepared according to PCT Publication No. WO2016 / 210190.

[0166] LNP formulations were prepared by injecting an ethanol solution of lipids into a dsRNA buffer in the same manner as described in U.S. Publication No. 2013-0022665, PCT Publication No. WO2019 / 090359, and PCT Publication No. WO2020 / 102668. These documents are expressly incorporated herein by reference in their entirety. The mean particle size (PS), polydispersity index (PDI), encapsulation efficiency for siRNA (%EE), and yield of each LNP formulation are shown in Table 2. The pKa value of each LNP was determined using a fluorescence-based assay of 2-(p-toluidino)-6-naphthalenesulfonic acid (TNS).

[0167] The in vitro activity of the LNP preparation was measured according to the following protocol:

[0168] Lung adenocarcinoma (A549) cells were cultured in vitro at 37°C in a 5% CO2 humidified incubator in the presence of DMEM medium (HyClone catalog number SH30243.01) containing 10% FBS (Invitrogen catalog number A4766801). The day before transfection, the cells were placed in 96-well plates in 2 × 10⁶ wells. 3Cells were seeded at a density of cells / well. The next day, siRNA / LNP complexes were prepared at room temperature, and 24 hours later, 10 μl of the siRNA / LNP complexes were added onto the cells. The 96-well plate was gently mixed, and incubated again in a humidified incubator with an atmosphere of 37°C and 5% CO₂. Target gene knockdown efficiency was determined by QRT-PCR at 24, 48, and 72 hours later. For total RNA isolation, the culture medium was removed from each well at each time point, and the cells were washed with 1×DPBS. Cell lysis: 50 μl of Cell-to-Ct lysis buffer (Life Technologies Catalog No. 4391851 C) was added onto the cells, and the mixture was incubated at room temperature for 5 minutes with gentle shaking. The cell lysate was treated with 5 μl of stop solution to terminate the cell lysis reaction. At the mRNA level, target gene knockdown was measured by QRT-PCR using a TAQMAN kit in accordance with the manufacturer's instructions.

[0169] The experimental results of the in vitro gene silencing study are shown in Table 2.

[0170] [Table 2] TIFF0007954317000030.tif152147

[0171] Example 32: Formulation Distribution Study LNP No. 1 (Compound No. 1 / Cholesterol / DSPC / DMG-PEG = 50 / 38.5 / 10 / 1.5 (mol%)) containing Fluc mRNA (TriLink, 5moU) was prepared using NanoAssemblr™ (Precision NanoSystems) according to the manufacturer's instructions. Balb / c mice (n=4) were given a single intravenous injection of LNP No. 1 at a dose of 0.5 mg / kg. Mice were anesthetized 6 to 8 hours after mRNA injection. The animals were then immediately sacrificed, and tissues (pancreas, spleen, liver, kidney, lung, and muscle) were collected. The tissues were homogenized in CCLR lysis buffer and centrifuged. The resulting supernatant was used for a luciferase activity assay using Promega E4510 assay reagent. The mRNA was transfected and translated mainly in the liver and spleen (see Figure 26).

[0172] Example 33: In vitro expression of Fluc mRNA An LNP formulation containing Fluc mRNA was prepared with the following composition: (Test compound / Cholesterol / DSPC / DMG-PEG2000) = 50 / 38 / 10 / 2 (mol%)

[0173] The test compound is any one of Compound Nos. 1, 2, and 4 to 30, R1, and R2.

[0174] LNP formulations were prepared by injecting an ethanol solution of lipids into a Fluc mRNA (TriLink, 5 moU) buffer solution in the same manner as described in U.S. Publication No. 2013-0022665, PCT Publication No. WO2019 / 090359, and PCT Publication No. WO2020 / 102668, which are expressly incorporated herein by reference in their entirety. The mean particle size (PS), polydispersity index (PDI), encapsulation efficiency to mRNA (%EE), and yield of each resulting LNP formulation are shown in Table 3 below. PS and PDI were obtained using a Malvern Zetasizer Nano-ZS ZEN 3600. %EE was obtained by Ribogreen fluorescence assay according to the GenVoy-ILM® User Guide by Precision NanoSystems.

[0175] In vitro expression of Fluc mRNA was measured according to protocol 1 or 2 below:

[0176] Protocol 1: Hep3B and Panc-1 cell lines were cultured in medium supplemented with 10% HI-FBS (Gibco reference no. 10082-147). EMEM medium (ATCC reference no. 30-2003) and DMEM medium (Gibco reference no. 11965-092) were used, respectively. On day 0, cells were seeded at a density of 5000 cells / well using 90 μL of cell mixture per well on a white, opaque 96-well TC-treated plate (Greiner reference no. 655083). The plates were placed overnight in a 37°C incubator with 5% CO2 to allow the cells to adhere. On day 1, mRNA / LNP complexes were equilibrated to room temperature, then diluted with DPBS (Gibco reference no. 14190-144) to create dose-response curves, and added to the plates at a volume of 10 μL / well. The plate was placed again in a 37°C incubator with 5% CO2 for 24 hours. On day 2, the buffer and substrate of the Promega luciferase assay system (reference no. E1501) were equilibrated to room temperature, combined, and then added to a SpectraMax L luminometer (Molecular Devices) injector. The plate was prepared according to the Promega kit guidelines by first removing the medium from each well, then gently rinsing the wells with DPBS, and finally adding 20 μL of 1× reporter lysis buffer (reference no. E397A) to each well. The plate was placed in the luminometer, and 100 μL of the luciferase buffer / substrate mixture per well was injected to obtain luminescence values. EC 50 The values ​​were determined by fitting a dose-response curve using a 4-parameter logistic model with GraphPad / Prism. EC of LNP formulations containing one of compounds 2, 4, 8, 14, 18, 19, and R2. 50 The values ​​were determined according to Protocol 1.

[0177] Protocol 2: Hep3B and Panc-1 cell lines were cultured in medium supplemented with 10% HI-FBS (Gibco reference no. 10082-147). EMEM medium (ATCC reference no. 30-2003) and DMEM medium (Gibco reference no. 11965-092) were used, respectively. On day 0, cells were seeded at a density of 1500 cells / well using a Multidrop Combi+ (Thermo Scientific) by adding 30 μL of cell mixture per well to a white, opaque 384-well TC-treated plate (USA Scientific reference no. 5678-1080). The plates were left overnight in a 37°C incubator with 5% CO2 to allow the cells to adhere. On day 1, mRNA / LNP complexes were equilibrated to room temperature, then diluted with DPBS (Gibco reference no. 14190-144) to create dose-response curves, and added to the plates at a volume of 3.3 μL / well. The plates were placed again in a 37°C incubator with 5% CO2 for 24 hours. On day 2, the ONE-Glo EX luciferase assay system (Promega reference number E8130) was equilibrated to room temperature and added. Plates were prepared according to the Promega kit guidelines by adding 33.3 μL of reagent mixture to each well. The plates were placed on a plate shaker for 3 minutes to ensure cell lysis. Once lysis was complete, the plates were placed in a luminometer (Molecular Devices) and luminescence values ​​were obtained. EC 50 The values ​​were determined by fitting a dose-response curve using a 4-parameter logistic model with GraphPad / Prism. EC of LNP formulations containing one of compounds 1, 5, 6, 7, 9, 10, 11, 12, 13, 15, 16, 17, 20-30, and R1. 50 The values ​​were determined according to Protocol 2. The experimental results are shown in Table 3 below.

[0178] [Table 3]

[0179] When LNP1a, 2a, 7a, 8a, 10a, 14a, 18a, 19a, 20a, 22a, 23a, 25a, 26a, 28a, 29a, or 30a is applied to HEP3B cells, EC 50 The values ​​were lower than when either one of the control LNPs (LNP R1a and LNP R2a) was applied to the same cells. When LNP2a, 4a, 5a, 7a, 8a, 9a, 11a, 13a, 14a, 16a, 17a, 18a, 19a, 20a, 21a, 22a, 24a, 25a, 26a, 27a, 29a, or 30a was applied to PANC-1 cells, EC 50 The values ​​were lower than when either one of the control LNPs (LNP R1a and LNP R2a) was applied to the same cells. When LNP6a, 12a, or 15a was applied to PANC-1 cells, EC 50 The values ​​were lower than when LNP R1a was applied to the same cells.

[0180] As used herein, the term “comprising” is synonymous with “including,” “containing,” or “characterized by,” and is comprehensive or open-ended, not excluding any additional undescribed elements or method steps.

[0181] The above description discloses some methods and materials of the present invention. The present invention is subject to modifications in methods and materials, as well as changes in manufacturing methods and apparatus. Such modifications will become apparent to those skilled in the art, considering this disclosure or practice of the present invention disclosed herein. Accordingly, the present invention is not intended to be limited to any specific embodiment disclosed herein, and the present invention encompasses all modifications and alternatives that fall within the true scope and spirit of the present invention.

[0182] All references cited herein, including but not limited to published and unpublished applications, patents, and literature references, are incorporated herein by reference in their entirety and become part of this Specified. In the event of any conflict between any publication or patent or patent application incorporated by reference and any disclosure contained herein, this Specified is intended to supersede and / or take precedence over any such conflicting material.

Claims

1. Compounds of formula I or pharmaceutically acceptable salts thereof: 【Chemistry 1】 [In the formula, A 1 teeth, 【Chemistry 2】 (In the formula, the arrow indicates connection to the carbonyl group.) X - (This is a pharmaceutically acceptable counter-anion.) Selected from the group consisting of, Each A 2 These are independently linear C4-C10 alkyl groups. m is an integer selected from the group consisting of 5, 6, 7, and 8. n is an integer selected from the group consisting of 2, 3, 4, and 5. The number of carbon atoms in the A4-A3-(CH2)n- is 15 to 21. A 3 is -OC(O)- or -C(O)O-, A 4 These are linear C10-C18 alkyl groups, linear C10-C18 alkenyl groups, or linear C10-C18 alkadienyl groups.

2. Each A 2 The compound according to claim 1, or a pharmaceutically acceptable salt thereof, which is the same as the compound according to claim 1.

3. A 1 but, 【Transformation 3】 (In the formula, arrows indicate connections to the carbonyl group.) A compound according to claim 1, or a pharmaceutically acceptable salt thereof, selected from the group consisting of the following.

4. A 1 but, 【Chemistry 4】 (In the formula, arrows indicate connections to the carbonyl group.) A compound according to claim 1, or a pharmaceutically acceptable salt thereof, selected from the group consisting of the following.

5. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, is selected from the group consisting of compound numbers 1 to 30 shown in Table 1 below: Table 1

6. below: Lipid nanoparticles, and Pharmaceutical active ingredients encapsulated in lipid nanoparticles A pharmaceutical composition comprising the compound described in claim 1, or a pharmaceutically acceptable salt thereof.

7. The pharmaceutical composition according to claim 6, wherein the active pharmaceutical ingredient is selected from the group consisting of siRNA, mRNA, antisense oligonucleotides, and miRNA.

8. A method for delivering a pharmaceutical active ingredient to cells, comprising the step of bringing cells into contact with a pharmaceutical composition according to claim 6, wherein the cells are cells of a monkey, rat, or mouse.

9. A method for delivering a pharmacoactive ingredient to a subject requiring delivery of the pharmacoactive ingredient, comprising the step of administering the pharmaceutical composition described in claim 6 to the subject, wherein the subject is a monkey, a rat, or a mouse.

Citation Information

Patent Citations

  • Compounds that target drug delivery and enhance siRNA activity

    JP2014529328A

  • Lipids for therapeutic drug delivery formulations

    JP2015523990A

  • Ionic compounds and compositions and their use

    JP2018524330A

  • Compounds and compositions for intracellular delivery of therapeutic agents

    JP2018532721A

  • Compounds and compositions for intracellular delivery of therapeutic agents

    JP2022501360A